Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-04T18:05:41.356Z Has data issue: false hasContentIssue false

References

Published online by Cambridge University Press:  18 December 2009

Edited by
Frank A. Sloan  and
Chee-Ruey Hsieh
Frank A. Sloan
Affiliation:
Duke University, North Carolina
Chee-Ruey Hsieh
Affiliation:
Academia Sinica, Taipei, Taiwan
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Pharmaceutical Innovation
Incentives, Competition, and Cost-Benefit Analysis in International Perspective
 , pp. 293 - 318
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abramocicz, M. 2003. “Perfecting Patient Prizes.” Vanderbilt Law Review 56(1):114–236.Google Scholar
Acemoglu, D., and Linn, J.. 2004. “Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry.” Quarterly Journal of Economics 119(3):1049–1090.CrossRefGoogle Scholar
Ackerberg, D. 2003. “Advertising, Learning, and Consumer Choice in Experience Good Market: A Structure Examination.” International Economic Review 44: 1007–1040.CrossRefGoogle Scholar
Addis, A., and Magrini, N.. 2002. “New Approaches to Analysing Prescription Data and Transfer Pharmacoepidemiological and Evidence-Based Reports to Prescribers.” Pharmacoepidemiology and Drug Safety 11: 721–726.CrossRefGoogle ScholarPubMed
Ades, A. 2003. “A Chain of Evidence with Mixed Comparisons: Models for Multi-parameter Syntheses and Consistency of Evidence.” Statistics in Medicine 22: 2995–3016.CrossRefGoogle Scholar
Advanced Markets Working Group. 2005. Making Markets for Vaccines: A Practical Plan to Spark Innovation for Global Health. Washington, DC: Center for Global Development & Global Health Policy Research Network. Available at www.cgdev.org/section/initiatives/_active/vaccinedevelopment/chapters.
Aghion, Philippe, and Tirole, Jean. 1994. “The Management of Innovation.” Quarterly Journal of Economics 109: 1185–1209.CrossRefGoogle Scholar
Aikin, Kathryn J. 2003. “The Impact of Direct-to-Consumer Prescription Drug Advertising on the Physician-Patient Relationship.” PowerPoint presentation. Available at www.fda.gov/cder/ddmac/aikin/sld001.htm.
Almond, D. 2003. “Is the 1918 Influenza Pandemic Over? Long-Term Effects of Utero Influenza Exposure in the Post-1940 U.S. Population.” Available at www.nber.org/∼almond. Last accessed January 21, 2005.
American Psychiatric Association. 2003. Practice Guidelines for the Treatment of Patients with Major Depression. Available at www.psych.org/psych_pract/treatg/pg/Depression2e.book.cfm. Last accessed July 18, 2004.
Anand, G. 2004. “How Drug's Rebirth as Treatment for Cancer Fueled Price Rises; Once-Demonized Thalidomide Boosts Celgene's Sales; Patients See Costs Soar; Avoiding AIDS Activists.” Wall Street Journal, November 15, 2004.Google Scholar
Anderson, G.F., and Hussey, P.S.. 2001. “Comparing Health System Performance in OECD Countries.” Health Affairs 20(5):219–232.CrossRefGoogle ScholarPubMed
Anderson, G.F., Reinhardt, U.E., Hussey, P.S., and Petrosyan, Varduhi. 2003. “It's the Prices, Stupid: Why the United States Is So Different from Other Countries.” Health Affairs 22(3):89–105.CrossRefGoogle ScholarPubMed
Angell, Marcia. 2004. The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York: Random House.Google Scholar
Anis, A.H., and Gagnon, Y.. 2000. “Using Economic Evaluations to Make Formulary Coverage Decisions: So Much for Guidelines.” PharmacoEconomics 18: 55–62.CrossRefGoogle ScholarPubMed
Anon, N.D. 2005. “The History of the Pasteur Institute.” Paris: Pasteur Institute. Available at www.pasteur.fr/english.html.
Anton, J.J., and Yao, D.A.. 1987. “Second Sourcing and the Experience Curve: Price Competition in Defense Procurement.” Rand Journal of Economics 18(1):57–76.CrossRefGoogle Scholar
Anton, J.J., and Yao, D.A.. 1989. “Split Awards, Procurement, and Innovation.” Rand Journal of Economics 20(4):538–552.CrossRefGoogle Scholar
Arnould, R., and L. DeBrock 2002. “An Overview of the Market for Vaccines in the United States.” Unpublished. Available from the Institute of Medicine, Washington, DC.
Arrow, Kenneth J. 1963. “Uncertainty and the Welfare Economics of Medical Care.” American Economic Review 53(5):941–973.Google Scholar
Avorn, Jerry. 2003. “Advertising and Prescription Drugs: Promotion, Education, and the Public Health.” Health Affairs – Web Exclusive W3: 104–108.Google Scholar
Avorn, Jerry. 2004. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Alfred A. Knopf.Google Scholar
Azoulay, Pierre. 2004. “Capturing Knowledge within and across Firm Boundaries: Evidence from Clinical Development.” American Economic Review 94 (5):1591–1612.CrossRefGoogle Scholar
Babazono, Akira, and Hillman, Alan L.. 1994. “A Comparison of International Health Outcomes and Health Care Spending.” International Journal of Technology Assessment in Health Care 10(3):376–381.CrossRefGoogle ScholarPubMed
Bagwell, Kyle, ed. 2001. The Economics of Advertising. International Library of Critical Writings in Economics, vol. 136. Cheltenham, U.K.: Edward Elgar Publishing.Google Scholar
Bain & Company. 2005. “The Pharma Innovation Divide: The High Cost of Europe's ‘Free Ride.’” Available at www.bain.com/bainweb/Consulting_Expertise/hot_topics/detail.asp?id=22. Last accessed October 28, 2005.
Baines, Darrin L, Tally, Keith H., and Whynes, David K.. 1997. Prescribing Budgets and Fundholding in General Practice. London: Office of Health Economics.Google Scholar
Batchlor, Elaine, and Laouri, Marianne. 2003. “Pharmaceutical Promotion, Advertising, and Consumers.” Health Affairs – Web Exclusive W3: 109–115.Google Scholar
Bear Stearns. 2002. “Attack of the Clones: 18 Years past Waxman-Hatch.” October 2. New York: Bear Stearns.
Becker, Elizabeth. 2003. “U.S. Is Battling for Higher Drug Prices Overseas.” New York Times, November 28.Google Scholar
Becker, Gary S., Phillipson, Thomas J., and Soares, Rodrigo R.. 2005. “The Quantity and Quality of Life and the Evolution of World Inequality.” American Economic Review 95(1):277–291.CrossRefGoogle ScholarPubMed
Benkler, Y. 2004. “Commons Based Strategies and the Problems of Patents.” Science 305: 1110–1111.CrossRefGoogle ScholarPubMed
Berndt, Ernst R. 2001. “The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?” Health Affairs 20(2):100–114.CrossRefGoogle ScholarPubMed
Berndt, E.R. 2002. “Pharmaceuticals in U.S. Health Care: Determinants of Quality and Price.” Journal of Economic Perspectives 16(4):45–66.CrossRefGoogle Scholar
Berndt, Ernst R. 2005. “To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs.” New England Journal of Medicine 352(4):325–328.CrossRefGoogle ScholarPubMed
Berndt, Ernst R., Bhattacharjya, Ashoke, Mishol, David, Arcelus, Almudena, and Lasky, Thomas. 2002. “An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts.” Journal of Mental Health Policy and Economics 5(1):3–17.Google ScholarPubMed
Berndt, Ernst R., Iain M. Cockburn, and Karen A. Grepin. 2005. “Biopharmaceutical R&D: Is the Productivity Decline Overstated?” Working paper, Conference on Health Reform in Europe and the U.S., Tufts Center, Talloues, France, July 2005.
Berndt, E., R. Glennerster, M.R. Kremer, J. Lee, R. Levine, G. Weizsacker, and H. Williams. 2005. “Advanced Markets for a Malaria Vaccine: Estimating Costs and Effectiveness.” National Bureau of Economic Research Working Paper 11288.
Berndt, E.R., and Hurwitz, J.A.. 2005. “Vaccine Advance Purchase Agreements for Low-Income Countries: Practical Issues.” Health Affairs 24(3):653–665.CrossRefGoogle ScholarPubMed
Berndt, Ernst R., Margaret K. Kyle, and Davina C. Ling. 2003. “The Long Shadow of Patent Expiration: Generic Entry and Rx to OTC Switches.” Chapter 8 in Scanner Data and Price Indexes, NBER Series on the Conference on Research in Income and Wealth, vol. 61, ed. by Feenstra, Robert C. and Shapiro, Matthew D., 229–267. Chicago: University of Chicago Press for the National Bureau of Economic Research.CrossRefGoogle Scholar
Beutels, P., Edmunds, W.J., Antoñanzas, F., Wit, G.A., Evans, D., Feilden, R., Fendrick, A.M., et al. 2002. “Economic Evaluation of Vaccination Programmes: A Consensus Statement Focusing on Viral Hepatitis.” PharmacoEconomics 20: 1–7.CrossRefGoogle ScholarPubMed
Birch, S., and Gafni, A.. 2002. “On Being NICE in the UK: Guidelines for Technology Appraisal for the NHS in England and Wales.” Health Economics 11: 185–191.CrossRefGoogle ScholarPubMed
Black, Douglas J., Smith, Cyril, and Townsend, Peter. 1982. Inequalities in Health: The Black Report. New York: Penguin Books.Google Scholar
Bloom, B.D.J. Wiertz, and Pauly, M.. 1986. “Cost and Price of Comparable Branded and Generic Pharmaceuticals.” Journal of the American Medical Association 256(18):2523–2530.CrossRefGoogle Scholar
Boardman, Anthony, Freedman, Ruth, and Eckel, Catherine. 1986. “The Price of Government Ownership: A Study of the Domtar Takeover.” Journal of Public Economics 31(3):269–286.CrossRefGoogle Scholar
Boardman, Anthony E., and Vining, Aidan R.. 1989. “Ownership and Performance in Competitive Environments: A Comparison of the Performance of Private, Mixed, and State-Owned Enterprises.” Journal of Law and Economics 32(1):1–33.CrossRefGoogle Scholar
Boswell, C. 2003. “InnoCentive and Web-Based Collaborative Innovation.” Chemical Market Reporter, April 14.Google Scholar
Bradford, D.F., and D.N. Shaviro. 2000. “The Economics of Vouchers,” in Vouchers and the Provision of Public Services, ed. by Steuerle, C.E., Ooms, Doorn, Peterson, George, and Reischauer, Robert D., 606–607. Washington, DC: Brookings Institution Press.Google Scholar
Branstetter, Lee G., Raymond Fisman, and C. Fritz Foley. 2003. “Do Stronger Intellectual Property Rights Increase International Technology Transfer? Empirical Evidence from U.S. Firm-Level Panel Data.” Unpublished paper, Columbia University Business School.
Breyer, S. 1982. Regulation and Its Reform. Cambridge, MA: Harvard University Press.Google Scholar
Brito, D.L., Sheshinski, E., and Intriligator, M.D.. 1991. “Externalities and Compulsory Vaccinations.” Journal of Public Economics 45: 69–90.CrossRefGoogle Scholar
Caffrey, Andrew. 2002. “Why Generics Can Cost States More Money.” Wall Street Journal, February 13.Google Scholar
Calfee, John E. 2002. “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs.” Journal of Public Policy & Marketing 21(2):174–193.CrossRefGoogle Scholar
Calfee, John E. 2003. “What Do We Know about Direct-to-Consumer Advertising of Prescription Drugs?” Health Affairs – Web Exclusive W3: 116–119.Google Scholar
Calfee, John E. 2004. “Paying for the Pills: How Much Does It Really Cost to Put a New Drug on the Market?” Nature 429: 807.CrossRefGoogle Scholar
Calfee, John E., Winston, Clifford, and Stempski, Randolph. 2002. “Direct-to-Consumer Advertising and the Demand for Cholesterol-Reducing Drugs.” Journal of Law and Economics 14(2):673–690.CrossRefGoogle Scholar
Carlton, Dennis W., and Jeffrey, M. Perloff. 1994. Modern Industrial Organization. 2nd ed. New York: HarperCollins College Division.Google Scholar
Caro, J., Klittich, W., McGuire, A., and Ford, I.. 1997. “The West of Scotland Coronary Prevention Study: Economic Benefit Analysis of Primary Prevention with Pravastatin.” British Medical Journal 315: 1577–1582.CrossRefGoogle ScholarPubMed
Caves, R.E., Whinston, M.D., and Hurwitz, M.. 1991. “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry.” Brookings Papers on Economic Activity Microeconomics (1991):1–66.CrossRefGoogle Scholar
Center for Global Development Advanced Market Commitment Working Group. 2005. “Making Markets for Vaccines: Ideas to Action.” Available at www.cgdev.org/Publications/vaccine/_files/MakingMarkets-complete.pdf. Last accessed April 28, 2005.
Claxton, K., Ginnelly, L., Sculpher, M., Philips, Z., and Palmer, S.. 2004. “A Pilot Study on the Use of Decision Theory and Value of Information Analysis as Past of the National Health Service Technology Assessment Programme. Health Technology Assessment 8(31) (whole issue).CrossRefGoogle Scholar
Clissold, D.B. 1995. “Prescription for The Orphan Drug-Act: The Impact of the FDA's 1992 Regulations and the Latest Congressional Proposals for Reform.” Food and Drug Law Journal 50(1):125–147.Google ScholarPubMed
Cochrane, A.L., Leger, A.S.St., and Moore, F.. 1978. “Health Service ‘Input’ and Mortality ‘Output’ in Developed Countries.” Journal of Epidemiology and Community Health 32(3):200–205.CrossRefGoogle ScholarPubMed
Cockburn, Iain M. 2004. “The Changing Structure of the Pharmaceutical Industry.” Health Affairs 23: 10–22.CrossRefGoogle ScholarPubMed
Cockburn, Iain, and Henderson, Rebecca. 1994. “Racing to Invest? The Economics of Competition in Ethical Drug Discovery.” Journal of Economics and Management Strategy 33: 481–519.CrossRefGoogle Scholar
Cockburn, Iain, and Henderson, Rebecca. 1996. Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery. Rand Journal of Economics 27: 32–60.Google Scholar
Cockburn, Iain M., and Henderson, Rebecca M.. 1998. “Absorptive Capacity, Co-Authoring Behavior, and the Organization of Research in Drug Discovery.” Journal of Industrial Economics 46: 157–182.CrossRefGoogle Scholar
Cockburn, Iain, and Rebecca Henderson. 1999. “The Economics of Drug Discovery,” in Ralph Landau et al., eds., Pharmaceutical Innovation, 308–330. Philadelphia: Chemical Heritage Press.
Cockburn, Iain, and Henderson, Rebecca. 2001. “Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research.” Journal of Health Economics 20(6):1033–1057.CrossRefGoogle ScholarPubMed
Cockburn, Iain M., Rebecca Henderson, and Scott Stern. 1999. “The Diffusion of Science Driven Drug Discovery, Organizational Change in Pharmaceutical Research.” National Bureau of Economic Research Working Paper 7359.
Cohen, J. 2002. “US Vaccine Supply Falls Seriously Short.” Science 295(5562):1998–2001.CrossRefGoogle Scholar
Cohen, J. 2004. “Vaccine Policy: Immunizing Kids against Flu May Prevent Deaths among the Elderly.” Science 306(5699):1123.CrossRefGoogle ScholarPubMed
Cohen, W.M., and Merrill, S.A.. 2003. Patents in the Knowledge-Based Economy: Committee on Intellectual Property Rights in the Knowledge-Based Economy. Washington, DC: National Academies Press, National Research Council (U.S.).Google Scholar
Cohen, Wesley M., Richard R. Nelson, and John P. Walsh. 2002. “Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not).” National Bureau of Economic Research Working Paper 7552.
Comanor, William S. 1964. “Research and Competitive Product Differentiation in the Pharmaceutical Industry in the United States.” Economica 31: 372–384.CrossRefGoogle Scholar
Comanor, William S. 1965. “Research and Technical Change in the Pharmaceutical Industry.” Review of Economics and Statistics 47(2):182–190.CrossRefGoogle Scholar
Conroy, Robert, Robert Harris, and Thomas Massaro. 1992. “Assessment of Risk and Capital Costs in the Pharmaceutical Industry.” Unpublished paper, University of Virginia, Darden School, June 30.
Corrigan, J. M., Greiner, A., and Erickson, S. M., eds. 2002. Fostering Rapid Advances in Health Care: Learning from System Demonstrations. Washington, DC: National Academies Press.Google Scholar
Covert, N. 2000. “Cutting Edge: A History of Fort Detrick.” Frederick, MD: Self-published. Available at www.detrick.army.mil/detrick/cutting_edge/index.cfm?chapter 12.
Crawford, Gregory S., and Shum, Matthew. 2005. “Uncertainty and Learning in Pharmaceutical Demand.” Econometrica 73(4):4.CrossRefGoogle Scholar
Cremieux, Pierre-Yves, Meilleur, Marie-Claude, Ouellette, Pierre, Petit, Patrick, Zelder, Martin, and Potvin, Ken. 2005. “Public and Private Pharmaceutical Spending as Determinants of Health Outcomes in Canada.” Health Economics 14: 107–116.CrossRefGoogle Scholar
Cremieux, Pierre-Yves, Pierre Ouellette, Marie-Clause Meilleur, Stephanie Leong, Paul Greenberg, and Howard Birnbaum. 2001. “Pharmaceutical Spending and Health Outcomes in the United States,” in Investing in Health: The Social and Economic Benefits of Health Care Innovation,” ed. by Farquhar, Irina, Summers, Kent, and Sorkin, Alan, 59–76. Oxford: Elsevier Science.Google Scholar
Cremieux, Pierre-Yves, Ouellette, Pierre, and Pilon, Caroline. 1999. “Health Care Spending as Determinants of Health Outcomes.” Health Economics 8: 627–639.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Currie, J., and Madrian, Brigitte C.. 1999. “Health, Health Insurance and the Labor Market,” in Handbook of Labor Economics, ed. by Orley Ashenfelter and David Card, 3309–3415. Amsterdam: Elsevier Science.Google Scholar
Cutler, David M. 2004. Your Money or Your Life: Strong Medicine for America's Health Care System. New York: Oxford University Press.Google Scholar
Cutler, David M., Deaton, Angus S., and Lleras-Muney, Adriana. 2006. “The Determinants of Mortality.” Journal of Economic Perspective 20(3):97–120.CrossRefGoogle Scholar
Cutler, David M., and Kadiyala, Srikanth. 2003. “The Return to Biomedical Research: Treatment and Behavioral Effects,” in Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 110–162. Chicago: University of Chicago Press.Google Scholar
Cutler, David M., and McClellan, Mark. 2001a. “Is Technological Change in Medicine Worth It?” Health Affairs 20(5):11–29.Google Scholar
Cutler, D.M., and McClellan, M.. 2001b. “Productivity Change in Health Care.” American Economic Review 91(2):281–286.CrossRefGoogle Scholar
Cutler, David, Mark McClellan, and Joseph Newhouse. 1997. “The Costs and Benefits of Intensive Treatment for Cardiovascular Disease.” Paper presented at AEI-Brookings Conference on Measuring the Prices of Medical Treatments, December 12.
Cutler, David, and Richardson, Elizabeth. 1997. “Measuring the Health of the U.S. Population.” Brookings Papers on Economic Activity: Microeconomics (1997):217–271.CrossRefGoogle Scholar
Cutler, David M., and Zeckhauser, R.. 2000. “The Anatomy of Health Insurance,” in Handbook of Health Economics, ed. by Antony J. Culyer and Joseph P. Newhouse, 563–643. Amsterdam: Elsevier.Google Scholar
Danzon, Patricia M. 2000. “Pharmaceutical Benefit Management: An Alternative Approach.” Health Affairs 19(1):24–25.CrossRefGoogle Scholar
Danzon, Patricia M. 2001. “Reference Pricing: Theory and Evidence,” in Reference Pricing and Pharmaceutical Policy, ed. by López-Casasnova, G. and Jönsson, B., 86–126.Google Scholar
Danzon, P. 2002. Pharmaceutical Price Regulation: National Policies versus Global Interests. Washington, DC: AEI Press.Google Scholar
Danzon, Patricia M., and Chao, Li-Wei. 2000. “Does Regulation Drive Out Competition in Pharmaceutical Markets?” Journal of Law and Economics 42(2):311–357.CrossRefGoogle Scholar
Danzon, Patricia M., and Furukawa, Michael. 2003. “Prices and Availability of Pharmaceuticals: Evidence from Nine Countries.” Health Affairs – Web Exclusive W3: 521–536.Google Scholar
Danzon, Patricia M., Nicholson, Sean, and Pereira, Nuno Sousa. 2005. “Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances.” Journal of Health Economics 24: 317–339.CrossRefGoogle ScholarPubMed
Danzon, P. M., Pereira, N.S., and Tejwani, S.S.. 2005. “Vaccine Supply: A Cross-National Perspective.” Health Affairs 24(3):706–717.CrossRefGoogle ScholarPubMed
Danzon, Patricia M., Wang, Y. Richard, and Wang, Liang. 2005. “The Impact of Price Regulation on the Launch Delay of New Drugs: Evidence from 25 Markets in the 1990s.” Health Economics 14: 269–292.CrossRefGoogle ScholarPubMed
Davidson, G., L.A. Blewett, K.T. Call, and SHADA Center. 2004. “Public Program Crowd-out of Private Coverage: What Are the Issues?” Research Synthesis Report No. 5. Available at www.rwjf.org/publications/synthesis/reports_and_briefs/issue5.html.
Davis, M.M., Ndiaye, S.M., Freed, G.L., Kim, C.S., and Clark, S.J.. 2003. “Influence of Insurance Status and Vaccine Cost on Physicians' Administration of Pneumococcal Conjugate Vaccine.” Pediatrics 112(3):521–526.CrossRefGoogle ScholarPubMed
Davis, M.M., Zimmerman, J.L., Wheeler, J.R.C., and Freed, G.L.. 2002. “Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations.” American Journal of Public Health 92(12):1982–1987.CrossRefGoogle ScholarPubMed
DeLaat, E.A.A. 1997. “Patents or Prizes: Monopolistic R&D and Asymmetric Information.” International Journal of Industrial Organization 15(3):369–390.CrossRefGoogle Scholar
Depression Guideline Panel, . 1993. Depression in Primary Care: Treatment of Major Depression. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.Google Scholar
Dickson, Michael, and Gagnon, Jean Paul. 2004. “Key Factors in the Rising Cost of New Drug Discovery and Development.” Nature Reviews 3: 417–428.Google ScholarPubMed
DiMasi, J.A., Hansen, R.W., and Grabowski, H.G.. 2003. “The Price of Innovation: New Estimates of Drug Development Costs.” Journal of Health Economics 22(2):151–185.CrossRefGoogle Scholar
DiMasi, J.A., Hansen, R.W., Grabowski, H.G., and Lasagna, L.. 1991. “Cost of Innovation in the Pharmaceutical Industry.” Journal of Health Economics 10(2):107–142.CrossRefGoogle ScholarPubMed
Dion, M.R., and Pavetti, L.. 2000. Access to and Participation in Medicaid and the Food Stamp Program: A Review of the Recent Literature. Washington, DC: Mathematica Policy Research.Google Scholar
Donaldson, C., Currie, G., and Mitton, C.. 2002. “Cost-Effectiveness Analysis in Health Care: Contraindications.” British Medical Journal 325: 891–894.CrossRefGoogle ScholarPubMed
Donohue, Julie M. 2003. “The Evolving Roles of Consumers and Consumer Protection: The History of Prescription Drug Advertising.” Milbank Quarterly 84(4):659–694.CrossRefGoogle Scholar
Donohue, Julie M., and Berndt, Ernst R.. 2004. “Effect of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants.” Journal of Public Policy & Marketing 23(2):115–127.CrossRefGoogle Scholar
Donohue, Julie M., Berndt, Ernst R., Rosenthal, Meredith, Epstein, Arnold M., and Frank, Richard G.. 2004. “Effects of Pharmaceutical Promotion on Adherence to Guideline Treatment of Depression.” Medical Care 42(2):1176–1185.CrossRefGoogle Scholar
Dorfman, Robert, and Steiner, Peter O.. 1954. “Optimal Advertising and Optimal Quality.” American Economic Review 44(5):826–836.Google Scholar
Dornbusch, Rudiger, and Fischer, Stanley. 1994. Macroeconomics. 6th ed. New York: McGraw-Hill.Google Scholar
Downs, Anthony. 1957. An Economic Theory of Democracy. New York: HarperCollins College Division.Google Scholar
Drummond, M.F., and Pang, F.. 2001. “Transferability of Economic Evaluation Results.” in Economic Evaluation in Health Care: Merging Theory with Practice, ed. by M.F. Drummond and A. McGuire, 256–327. Oxford: Oxford University Press.Google Scholar
Drummond, M.F., and Sculpher, M.J.. 2005. “Common Methodological Flaws in Economic Evaluations.” Medical Care 43(4):5–14.CrossRefGoogle ScholarPubMed
Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., and Stoddart, G.L.. 2005. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press.Google Scholar
D'Souza, Juliet, and Megginson, William L.. 1999. “The Financial and Operating Performance of Privatized Firms during the 1990s.” Journal of Finance 54(4):1397–1438.CrossRefGoogle Scholar
Dubois, Robert W. 2003. “Pharmaceutical Promotion: Don't Throw the Baby Out with the Bathwater.” Health Affairs – Web Exclusive W3: 96–103.Google Scholar
Dubois, Robert W., Chawla, Anita J., Neslusan, Cheryl A., et al. 2000. “Explaining Drug Spending Trends: Does Perception Match Reality?” Health Affairs 19: 231–239.CrossRefGoogle ScholarPubMed
Duggan, Mark. 2005. “Do New Prescription Drugs Pay for Themselves? The Case of Second-Generation Antipsychotics.” Journal of Health Economics 24: 1–31.CrossRefGoogle ScholarPubMed
Ehrlich, Isaac, Gallais-Hamonno, Georges, Liu, Zhiqiang, and Lutter, Randall. 1994. “Productivity Growth and Firm Ownership: An Analytical and Empirical Investigation.” Journal of Political Economy 102(5):1006–1038.CrossRefGoogle Scholar
Ellison, G.S., and F. Ellison. 2000. “Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration.” Working paper, MIT, Cambridge, MA.
Ellison, Sara Fisher, and Wallace P. Mullin. 1997. “Gradual Incorporation of Information into Stock Prices: Empirical Strategies.” National Bureau of Economic Research Working Paper 6218.
Emmons, Willis A., and Ashok Nimgade. 1991. “Burroughs Wellcome and AZT.” Harvard Business School Case No. 9-792-004, Cambridge, MA.
Enserink, M. 2004. “Influenza: Crisis Underscores Fragility of Vaccine Production System.” Science 306(5695):385.CrossRefGoogle ScholarPubMed
EPIC Investigators, . 1994. “Use of Monoclonal Antibody Directed against the Platelet Glycoprotein lib/111a Receptor in High-Risk Coronary Angioplasty.” New England Journal of Medicine 330: 956–961.Google Scholar
Fama, E.F. 1980. “Agency Problems and the Theory of the Firm.” Journal of Political Economy 88(2):288–307.CrossRefGoogle Scholar
Fama, E.F., Fisher, L., Jensen, M., and Roll, R.. 1969. “The Adjustment of Stock Prices to New Information.” International Economic Review 10(1):1–21.CrossRefGoogle Scholar
Farber, Henry S., and Brazerman, Max H.. 1986. “The General Basis of Arbitrator Behavior: An Empirical Analysis of Conventional and Final-Offer Arbitration.” Econometrica 54: 819–844.CrossRefGoogle Scholar
Farlow, A. 2004. “Analysis of the Problems of R&D Finance for Vaccines and an Appraisal of Advance Purchase Commitments.” Preprint. Oxford: University of Oxford. Available at www.economics.ox.ac.uk/members/andrew.farlow/VaccineRD.pdf#search='farlow%20and%20analysis%20of%20the%20problems.
Farlow, Andrew, Donald W. Light, Richard T. Mahoney, and Roy Widdus. 2005. “Concerns Regarding the ‘Making Markets for Vaccines’ Submission to the Commission on Intellectual Property Rights, Innovation and Public Health.” Available at www.who.int/intellectualproperty/en/. Last accessed May 10, 2005.
Farquhar, Irina, Summers, Kent, and Sorkin, Alan, eds. 2001. Benefits of Health Care Innovation. Oxford: Elsevier Science.Google Scholar
Federal Trade Commission, . 2002. Generic Competition Prior to Patent Expiration: An FTC Study. Washington, DC: Federal Trade Commission.Google Scholar
FinFacts. Global/World Income per Capita/Head 2005. 2005. Available at www.finfacts.com/biz10/globalworldincomepercapita.htm. Last accessed October 20, 2005.
Finkel, M., and Buron, L.. 2001. Study on Section 8 Voucher Success Rates. Cambridge, MA: Diane Publishing.Google Scholar
Finkelstein, A. 2004. “Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry.” Quarterly Journal of Economics 119(2):527–564.CrossRefGoogle Scholar
Forbes, Steve. 2005. “Rich Freeloader Countries – France, German, Canada – Rob America on Health Care.” USA Next. Available at www.usanext.org/full_story.cfm?areticle_id=16&category_id=3. Last accessed October 30, 2005.
Fortune Magazine. 2005. The 2005 Fortune 500: Most Profitable Industries: Return on Revenues. Available at www.fortune.com/fortune/subs/fortune500/topperformers/industrysnapshot/0,23619,prof_pct_rev,00.html.
Frank, John W., and J. Fraser Mustard. 1998. “The Determinants of Health from a Historical Perspective.” The Founders' Network. Available at www.founders.net/fn/papers.nsf.
Frank, R.G., Dewa, C., Holt, E., et al. 1995. “The Demand for Childhood Immunizations: Results from the Baltimore Immunization Study.” Inquiry 32(2):164–173.Google ScholarPubMed
Frank, R.G., and Salkever, D.S.. 1992. “Pricing, Patent Loss and the Market for Pharmaceuticals.” Southern Economic Journal 59: 165–179.CrossRefGoogle Scholar
Frank, R.G., and Salkever, D.S.. 1997. “Generic Entry and Pricing of Pharmaceuticals.” Journal of Economics and Management Strategy 6(1):75–90.CrossRefGoogle Scholar
Frech, H.E. III, and Miller, Richard D., Jr. 1999. The Productivity of Health Care and Pharmaceuticals: An International Comparison. Washington, DC: AEI Press.Google Scholar
Freed, G.L., Clark, S.J., Pathman, D.E., Schectman, R., and Serling, J.. 1999. “Impact of North Carolina's Universal Vaccine Purchase Program by Children's Insurance Status.” Archives of Pediatric and Adolescent Medicine 153(7):748–754.CrossRefGoogle ScholarPubMed
Freed, G., and A. Cowan. 2002. “State-Level Perspectives on Vaccine Purchase Financing.” Unpublished. Available from the Institute of Medicine, Washington, DC.
Freed, G.L., Davis, M.M., Andreae, M.C., Bass, S., and Weinblatt, H.. 2002. “Reimbursement for Prevnar: A Modern-Day Version of Hercules and the Hydra.” Pediatrics 110(2):399–400.CrossRefGoogle ScholarPubMed
Fuchs, Victor R., and Zeckhauser, Richard. 1987. “Valuing Health: A ‘Priceless’ Commodity.” American Economic Review 77(2):263–268.Google ScholarPubMed
Gafni, A., and Birch, S.. 1993. “Guidelines for the Adoption of New Technologies: A Prescription for Uncontrolled Growth in Expenditures and How to Avoid the Problem.” Canadian Medical Association Journal 148(6):913–917.Google ScholarPubMed
Gahart, Martin T., Duhamel, Louise M., Dievler, Anne, and Price, Roseanne. 2003. “Examining the FRDA's Oversight of Direct-to-Consumer Advertising.” Health Affairs – Web Exclusive W3: 120–123.Google Scholar
Gallini, N., and Scotchmer, S.. 2002. “Intellectual Property: When Is It the Best Incentive Mechanism?” in Innovation Policy and the Economy, ed. by A. Jaffe, J. Lerner, and S. Stern, 2:51–78. Cambridge, MA: MIT Press.Google Scholar
Gambardella, Alfonso. 1995. Science and Innovation: The U.S. Pharmaceutical Industry during the 1980s. Cambridge: Cambridge University Press.CrossRefGoogle Scholar
George, B., Harris, A., and Mitchell, A.. 2001. “Cost-Effectiveness Analysis and the Consistency of Decision-Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996).” PharmacoEconomics 19(11):1103–1109.CrossRefGoogle Scholar
Georges, P., Ann, A. Margaret, Jeffrey, P.D., Michael, D.D., et al. 2003. “Strengthening the Supply of Routinely Recommended Vaccines in the United States: Recommendations from the National Vaccine Advisory Committee.” Journal of the American Medical Association 290(23):3122–3128.Google Scholar
Giaccotto, Carmelo, Santerre, Rexford E., and Vernon, John A.. 2005. “Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry.” Journal of Law and Economics 48(1):195–214.CrossRefGoogle Scholar
Giffin, R., Stratton, K., and Chalk, R.. 2004. “Childhood Vaccine Finance and Safety Issues.” Health Affairs 23(5):98–111.CrossRefGoogle ScholarPubMed
Glassman, James K. 2005. “Free Riding Isn't Free.” Available at www.techcentralstation.com/022304F.html. Last accessed October 28, 2005.
Glied, Sherry. 2003. “Health Care Costs: On the Rise Again.” Journal of Economic Perspective 17(2):125–148.CrossRefGoogle Scholar
Global Alliance for TB Drug Development, . 2001. Economics of TB Drug Development. New York: Global Alliance for TB Drug Development. Available at http://66.216.124.114/pdf/Economics%20Report%20Full%20(final).pdf.Google Scholar
Global Health Policy Research Network. 2004. “Making Markets for Vaccines.” Pull Mechanisms Working Group. Available at www.cgdev.org/globalhealth/proj_pull.cfm.
Gold, M., Siegel, J.E., Russell, L.B., and Weinstein, M.C., eds. 1996. Cost Effectiveness in Health and Medicine. Oxford: Oxford University Press.Google Scholar
Goodman, J.C., and Musgrave, G.L.. 1987. Freedom of Choice in Health Insurance. Dallas: National Center for Policy Analysis.Google Scholar
Goolsbee, Austan. 1988. “Does Government R&D Policy Mainly Benefit Scientists and Engineers?” American Economic Review 88(2):298–302.Google Scholar
Grabowski, Henry. 2004. “Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures.” PharmacoEconomics 22(Suppl. 2):15–24.CrossRefGoogle ScholarPubMed
Grabowski, Henry. 2005. “Encouraging the Development of New Vaccines.” Health Affairs 24(3):697–700.CrossRefGoogle ScholarPubMed
Grabowski, Henry, Cockburn, Iain, and Long, Genia. 2006. “The Market for Follow-On Biologics: How Will It Evolve.” Health Affairs 25(5):1291–1301.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Kyle, Margaret. 2006. “Generic Competition and Market Exclusivity Periods in Pharmaceuticals.” Managerial and Decision Economics, forthcoming.Google Scholar
Grabowski, Henry, and Mullins, C. Daniel. 1997. “Pharmacy Benefit Management Cost-Effectiveness Analysis and Drug Formulary Decisions.” Social Science and Medicine 45(4):535–544.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Vernon, John. 1986. “Longer Patents for Lower Imitation Barriers: The 1984 Drug Act.” American Economic Review: Papers and Proceedings 76(2):195–198.Google Scholar
Grabowski, Henry, and Vernon, John M.. 1990. “A New Look at the Return and Risks to Pharmaceutical R&D.” Management Science 36: 804–821.CrossRefGoogle Scholar
Grabowski, Henry, and Vernon, John. 1992. “Brand Loyalty Entry and Price Competition in Pharmaceuticals after the 1984 Act.” Journal of Law and Economics 35(2):331–350.CrossRefGoogle Scholar
Grabowski, Henry, and Vernon, John M.. 1994. “Returns on New Drug Introductions in the 1980s.” Journal of Health Economics 13: 383–406.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Vernon, John. 1996. “Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade.” PharmacoEconomics 10 (Suppl. 2):110–123.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Vernon, John. 2000. “Effective Patent Life in Pharmaceuticals.” International Journal of Technology Management 19(1–2):98–120.CrossRefGoogle Scholar
Grabowski, Henry, Vernon, John M., and Thomas, Lacy Glenn. 1978. “Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry.” Journal of Law and Economics 21(1):133–163.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Wang, Richard. 2006. “The Quantity and Quality of Worldwide New Drug Introductions: 1982–2003.” Health Affairs 25(2):452–460.CrossRefGoogle ScholarPubMed
Greene, Jeremy A. 2004. “Attention to ‘Details’: Etiquette and the Pharmaceutical Salesman in Postwar America.” Social Studies in Science 34(2):271–292.CrossRefGoogle Scholar
Gruber, J. 1994. “The Incidence of Mandated Maternity Benefits.” American Economic Review 84(3):622–642.Google ScholarPubMed
Gruber, J., ed. 2000. “Health Insurance and the Labor Market,” in Handbook of Health Economics, ed. by Antony J. Culyer and Joseph P. Newhouse, 645–706. Amsterdam: Elsevier Science.Google Scholar
Guedj, Ilan, and David Scharfstein. 2004. “Organizational Scope and Investment: Evidence from the Drug Development Strategies of Biopharmaceutical Firms.” National Bureau of Economic Research Working Paper.
Gupta, Nandini. 2002. “Partial Privatization and Firm Performance.” Unpublished working paper, Columbia University. August. Available at www-1.gsb.columbia.edu/divisions/management/seminar/papers/gupta.pdf.
Hall, Bronwyn, H. 1993, “R&D Tax Policy during the Eighties: Success or Failure?” in Tax Policy and the Economy 7, ed. by James Poterba, 1–35. Cambridge, MA: MIT Press.Google Scholar
Hall, Bronwyn H., and Reenen, John. 2000. “How Effective Are Fiscal Incentives for R&D? A New Review of the Evidence.” Research Policy 29: 449–469.CrossRefGoogle Scholar
Hall, Robert E., and Jones, Charles I.. 1999. “Why Do Some Countries Produce So Much More Output per Worker than Others?” Quarterly Journal of Economics 114(1):83–116.CrossRefGoogle Scholar
Hansen, Ronald W. 1979. “The Pharmaceutical Development Process: Estimates of Development Costs and Times and the Effects of Proposed Regulatory Changes,” in Issues in Pharmaceutical Economics, ed. Robert I. Chien, 151–187. Boston: Lexington Books.Google Scholar
Hart, Oliver D., Shleifer, Andrei, and Vishny, Robert W.. 1997. “The Proper Scope of Government: Theory and an Application to Prisons.” Quarterly Journal of Economics 112(4):1126–1161.CrossRefGoogle Scholar
Hassett, Kevin, and R. Glenn Hubbard. 1996. “Tax Policy and Investment.” Unpublished paper, Federal Reserve Board of Governors and Columbia University Business School.
Heffler, Stephen, Smith, Sheila, Keehan, Sean, Borger, Christine, Clemens, M. Kent, and Truffer, Christopher. 2005. “U.S. Health Spending for 2004–2014.” Health Affairs – Web Exclusive W5: 74–85.Google Scholar
Henderson, Rebecca, and Cockburn, Iain. 1996. “Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery.” RAND Journal of Economics 27(1):32–59.CrossRefGoogle ScholarPubMed
Hill, S.R., Mitchell, A.S., and Henry, D.A.. 2000. “Problems with the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme.” Journal of the American Medical Association 283: 2116–2121.CrossRefGoogle ScholarPubMed
Hinman, A. 2004. “Institute of Medicine Report on Financing Vaccines in the 21st Century: National Vaccine Advisory Committee/National Vaccine Program Office Response.” Available at www.hhs.gov/nvpo/nvac/NVAC-IOM100604.htm.
Hinman, A. 2005. “Addressing the Vaccine Financing Conundrum.” Health Affairs 24(3):701–704.CrossRefGoogle ScholarPubMed
Hoek, Janet, Gendall, Philip, and Calfee, John. 2004. “Direct-to-Consumer Advertising of Prescription Medicines in the United States and New Zealand: An Analysis of Regulatory Approaches and Consumer Responses.” International Journal of Advertising 23: 197–227.CrossRefGoogle Scholar
Hollis, A. 2005a. “An Efficient Reward System for Pharmaceutical Innovation.” Preprint. Available at http://econ.ucalgary.ca/fac-files/ah/drugprizes.pdf#search='hollis%20and%20an%20efficient%20reward%20system.
Hollis, A. 2005b. “An Optional Reward System for Neglected Disease Drugs.” Mimeo, University of Calgary.
Hollon, Matthew F. 1999. “Direct-to-Consumer Prescription Drugs: Creating Consumer Demand.” Journal of the American Medical Association 281(4):382–384.CrossRefGoogle ScholarPubMed
Holmstrom, Bengt, and Tirole, Jean. 1993. “Market Liquidity and Performance Monitoring.” Journal of Political Economy 101: 678–709.CrossRefGoogle Scholar
Hotz, J., Ahituv, A., and Philipson, T.. 1996. “The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS.” Journal of Human Resources 21(4):869–897.Google Scholar
Hsieh, Chee-Ruey, and Frank A. Sloan. 2006. “Adoption of Pharmaceutical Innovation and the Growth of Drug Expenditure: The Taiwanese Experience.” Working Paper, Duke University.
Hsu, J.C., and E.S. Schwartz. 2003. “A Model of R&D Valuation and the Design of Research Incentives.” National Bureau of Economic Research Working Paper 10041.
Hubbard, R.G., Skinner, J., and Zeldes, S.P.. 1995. “Precautionary Saving and Social Insurance.” Journal of Political Economy 103: 360–399.CrossRefGoogle Scholar
Hudson, John. 2000. “Generic Take-Up in the Pharmaceutical Market Following Patent Expiry: A Multi-Country Study.” International Review of Law and Economics 20: 205–221.CrossRefGoogle Scholar
Hume, C., and Schmitt, W.. 2001. “Pharma's Prescription.” Chemical Week, April 11, 21.Google Scholar
Hurwitz, Mark A., and Caves, Richard E.. 1988. “Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals.” Journal of Law and Economics 31, no. 5: 299–320.CrossRefGoogle Scholar
Huskamp, H.A., Rosenthal, M.B., Frank, R.G., and Newhouse, J.P.. 2000. “The Medicare Prescription Drug Benefit: How Will the Game Be Played?” Health Affairs 19(2):8–23.CrossRefGoogle ScholarPubMed
Iglehart, John K., ed. 2004. “Variations Revisited: A Supplement to Health Affairs.” Health Affairs – Web Exclusive 23: 3–4.Google Scholar
Iizuka, Toshi. 2004. “What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs?” Journal of Industrial Economics 52(3):349–379.CrossRefGoogle Scholar
Iizuka, Toshi, and Ginger Z. Jin. 2003. “The Effects of Direct-to-Consumer Advertising in the Prescription Drug Markets.” Unpublished working paper, Vanderbilt University, Owen Graduate School of Management, September 29.
Iizuka, Toshi, and Jin, Ginger Z.. 2005a. “The Effect of Prescription Drug Advertising on Doctor Visits.” Journal of Economics and Management Strategy, forthcoming.CrossRefGoogle Scholar
Iizuka, Toshi, and Ginger Z. Jin. 2005b. “Direct to Consumer Advertising and Prescription Choice.” Working paper, Vanderbilt University, Owen Graduate School of Management.
IMS, . 2004. Global Pharmaceutical Review. October. London.Google Scholar
IMS Intelligence. 2005. Chart 1. PowerPoint Presentation Supplied via e-mail by Raymond Hill of IMS, May 21.
Institute of Medicine, . 2000. Calling the Shots: Immunization Finance Policies and Practices. Washington, DC: National Academies Press.Google Scholar
Institute of Medicine, . 2003. Hidden Costs, Value Lost: Uninsurance in America. Washington, DC: National Academies Press, 2003.Google Scholar
Institute of Medicine, . 2004. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press.Google Scholar
Institute of Medicine, , Corrigan, J., Greiner, A., and Erickson, S.M.. 2002. Fostering Rapid Advances in Health Care: Learning from System Demonstrations. Washington, DC: National Academies Press.Google Scholar
Ives, D., Lave, J., Traven, N., and Kuller, L.. 1994. “Impact of Medicare Reimbursement on Influenza Vaccination Rates in the Elderly.” Preventive Medicine 23: 134–141.CrossRefGoogle ScholarPubMed
Jensen, Elizabeth J. 1987. “Research Expenditures and the Discovery of New Drugs.” Journal of Industrial Economics 36: 83–95.CrossRefGoogle Scholar
Jensen, G.A., and Morrisey, M.A.. 1999. “Employer-Sponsored Health Insurance and Mandated Benefit Laws.” Milbank Quarterly 77(4):425–459.CrossRefGoogle ScholarPubMed
Jewkes, John, Sawyers, David, and Stillerman, Richard. 1958. The Sources of Invention. London: Macmillan.Google Scholar
Jones, Charles. 1998. Introduction to Economic Growth. New York: W.W. Norton.Google Scholar
Joskow, P.L. 1989. “Regulatory Failure, Regulatory Reform, and Structural-Change in the Electrical-Power Industry.” Brookings Papers on Economic Activity (1998):125–208.CrossRefGoogle Scholar
Juhl, R.P. 2000. “Prescription to Over-the-Counter Switch: A Regulatory Perspective.” Clinical Therapeutics 20(Supp. C):111–117.CrossRefGoogle Scholar
Kahn, A. 1971. The Economics of Regulation: Principles and Institutions. New York: Wiley.Google Scholar
Kaiser Family Foundation. 2001. Prescription Drug Trends: A Chartbook UpdateWashington, DC.
Kaiser Family Foundation. 2002. Employer Health Benefits: 2002 Annual Survey. Washington, DC.
Kaiser Family Foundation. 2005. Prescription Drug Coverage for Medicare Beneficiaries: A Summary of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Available at www.kff.org/medicare/6112.cfm. Last accessed November 5, 2005.
Kanavos, Panos, and Reinhardt, Uwe E.. 2003. “Reference Pricing For Drugs: Is It Compatible with U.S. Health Care?” Health Affairs 22(3):16–30.CrossRefGoogle ScholarPubMed
Kettler, Hannah E. 1999. “Updating the Cost of a New Chemical Entity.” London: Office of Health Economics.
Keynes, John Maynard. 1936. The General Theory of Employment, Interest, and Money. London: Macmillan.Google Scholar
Kim, Jong-Il, and Lau, Lawrence J.. 1994. “The Sources of Economic Growth of the East Asian Newly Industrialized Countries.” Journal of the Japanese and International Economies 8: 235–271.CrossRefGoogle Scholar
Kitch, E.W. 1977. “The Nature and Function of the Patent System.” Journal of Law and Economics 10: 265–290.CrossRefGoogle Scholar
Klein, Daniel B. 2005. “Policy Medicine versus Policy Quackery: Economists against the FDA.” Knowledge, Technology, and Policy 31(1):92–101.Google Scholar
Klick, J., and Sara Markowitz. 2003. “Are Mental Health Insurance Mandates Effective? Evidence from Suicides.” National Bureau of Economic Research Working Paper 9994.
Kobelt, G., Jönsson, L., Young, A., and Eberhardt, K.. 2003. “The Cost-Effectiveness of Infliximab (Remicade) in the Treatment of Rheumatoid Arthritis in Sweden and the United Kingdom Based on the ATTRACT Study.” Rheumatology 42: 326–335.CrossRefGoogle ScholarPubMed
Kravitz, Richard I., Epstein, Ronald M., Feldman, Mitchell D., Franz, Carol E., Azari, Rahman, Wilkes, Michael S., Hinton, Ladson, and Franks, Peter. 2005. “Influence of Patients' Requests for Direct-to-Consumer Advertised Antidepressants: A Randomized Controlled Trial.” Journal of the American Medical Association 293(16):1995–2002.CrossRefGoogle ScholarPubMed
Kreling, D.H., T. Collins, H. Lipton, and K.C. Hertz. 1996. “Assessing the Impact of Pharmacy Benefit Managers.” HCFA Contract Report, HCFA 95-023/PW, September 30.
Kremer, M. 1998. “Patent Buyouts: A Mechanism for Encouraging Innovation.” Quarterly Journal of Economics 113(4):1137–1167.CrossRefGoogle Scholar
Kremer, M. 2000a. “Creating Markets for New Vaccines Part I: Rationale.” National Bureau of Economic Research Working Paper 7716.
Kremer, M. 2000b. “Creating Markets for New Vaccines Part II: Design Issues.” National Bureau of Economic Research Working Paper 7717.
Kremer, M., and Glennerster, R.. 2004. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton, NJ: Princeton University Press.Google Scholar
Kremer, M., and C.M. Snyder. 2003. “Why Are Drugs More Profitable than Vaccines?” National Bureau of Economic Research Working Paper 9833.
Kronick, R., and Gilmer, T.. 2002. “Insuring Low-Income Adults: Does Public Coverage Crowd Out Private?” Health Affairs 21(1):225–239.CrossRefGoogle ScholarPubMed
Laffont, J.-J., and Tirole, J.. 1993. A Theory of Incentives in Procurement and Regulation. Cambridge, MA: MIT Press.Google Scholar
Landau, Ralph, et al. 1999. Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press.Google Scholar
Lanjouw, J. 2004. “Outline of Foreign Filing License Approach.” Washington, DC: Center for Global Development & Global Health Policy Research Network. Available at www.cgdev.org/docs/FFLOutline.pdf.
Lanjouw, J.O., and M. MacLeod. 2005. “Statistical Trends in Pharmaceutical Research for Poor Countries.” Available at www.who.int/intellectualproperty/studies. Last accessed May 10, 2005.
Learner, Josh, and Merges, Robert P.. 1998. “The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry.” Journal of Industrial Economics 46: 125–156.CrossRefGoogle Scholar
Learner, Josh, and Alexander Tsai. 2000. “Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances.” National Bureau of Economic Research Working Paper W7464.
Leffler, Keith B. 1981. “Promotion or Information? The Economics of Prescription Drug Advertising.” Journal of Law and Economics 24(2):45–74.CrossRefGoogle Scholar
Levin, Richard C., Klevorick, Alvin K., Nelson, Richard R., and Winter, Sidney G.. 1987. “Appropriating the Returns from Industrial Research and Development.” Brookings Papers on Economic Activity 3: 783–820.CrossRefGoogle Scholar
Lichtenberg, Frank R. 1984. “The Relationship between Federal Contract R&D and Company R&D.” American Economic Review 74(2):73–78.Google Scholar
Lichtenberg, Frank R. 1986. “Energy Prices and Induced Innovation.” Research Policy 15: 67–75.CrossRefGoogle Scholar
Lichtenberg, Frank R. 1987. “Changing Market Opportunities and the Structure of R&D Investment: The Case of Energy.” Energy Economics 9(3):154–158.CrossRefGoogle Scholar
Lichtenberg, Frank R. 1988. “The Private R&D Investment Response to Federal Design and Technical Competitions.” American Economic Review 78(3):550–559.Google Scholar
Lichtenberg, Frank R. 1996. “The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality.” National Bureau of Economic Research Working Paper 5418.
Lichtenberg, Frank R. 2001a. “The Allocation of Publicly Funded Biomedical Research,” in Medical Care Output and Productivity, Studies in Income and Wealth vol. 62, ed. by Ernst Berndt and David Cutler, 565–589. Chicago: University of Chicago Press.Google Scholar
Lichtenberg, Frank R. 2001b. “The Effect of New Drugs on Mortality from Rare Diseases and HIV.” National Bureau of Economic Research Working Paper 8677.
Lichtenberg, Frank R. 2003a. “Pharmaceutical Innovation, Mortality Reduction, and Economic Growth.” in Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 74–109. Chicago: University of Chicago Press.Google Scholar
Lichtenberg, Frank R. 2003b. “The Effect of New Drugs on HIV Mortality in the U.S., 1987–1998.” Economics and Human Biology 1: 259–266.CrossRefGoogle Scholar
Lichtenberg, Frank R. 2003c. “The Benefits to Society of New Drugs: A Survey of the Econometric Evidence.” Proceedings of the Federal Reserve Bank of Dallas (September):43–59.Google Scholar
Lichtenberg, Frank R. 2004a. “Public Policy and Innovation in the U.S. Pharmaceutical Industry,” in Public Policy and the Economics of Entrepreneurship, ed. by Douglas Holtz-Eakin and Harvey S. Rosen, 83–113. Cambridge, MA: MIT Press.Google Scholar
Lichtenberg, Frank R. 2004b. “Sources of U.S. Longevity Increase, 1960–2001.” Quarterly Review of Economics and Finance 44(3):369–389.CrossRefGoogle Scholar
Lichtenberg, Frank R. 2005a. “Pharmaceutical Innovation and the Burden of Disease in Developed and Developing Countries.” Journal of Medicine and Philosophy 30(6):663–690.CrossRefGoogle Scholar
Lichtenberg, Frank R. 2005b. “The Impact of New Drug Launches on Longevity: Evidence from Longitudinal Disease-level Data from 52 Countries, 1982–2001.” International Journal of Health Care Finance and Economics 5(1):47–73.CrossRefGoogle Scholar
Lichtenberg, Frank R., and Suchin Virabhak. 2002. “Pharmaceutical Embodied Technical Progress, Longevity, and Quality of Life: Drugs as “Equipment for Your Health.” National Bureau of Economic Research Working Paper 9351.
Lichtenberg, F., and J. Waldfogel. 2003. “Does Misery Love Company? Evidence from Pharmaceutical Markets before and after the Orphan Drug Act.” National Bureau of Economic Research Working Paper 9750.
Light, Donald W., and Warburton, Rebecca N.. 2005. “Extraordinary Claims Require Extraordinary Evidence.” Journal of Health Economics 24(5):1030–1033.CrossRefGoogle ScholarPubMed
Ling, Davina C., Berndt, Ernst R., and Kyle, Margaret K.. 2002. “Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales.” Journal of Law and Economics 14: 691–723.CrossRefGoogle Scholar
Livernois, J.R. 1988. “Estimates of Marginal Discovery Costs for Oil and Gas.” Canadian Journal of Economics 21(2):379–393.CrossRefGoogle Scholar
López-Casasnovas, G., and Jönsson, B., eds. 2001. Reference Pricing and Pharmaceutical Policy. Barcelona: Springer Verlag Ibéria.Google Scholar
López-Casasnovas, G., and Puig-Junoy, J.. 2001. “Review of the Literature on Reference Pricing,” in Reference Pricing and Pharmaceutical Policy, ed. G. López-Casasnovas and B. Jönsson, 1–41. Barcelona: Springer Verlag Ibéria.Google Scholar
Lo Sasso, A.T., and Buchmueller, T.C.. 2004. “The Effect of the State Children's Health Insurance Program on Health Insurance Coverage.” Journal of Health Economics 23(5):1059–1082.CrossRefGoogle ScholarPubMed
Luman, E.T., Barker, L.E., Shaw, K.M., et al. 2005. “Timeliness of Childhood Vaccinations in the United States: Days Undervaccinated and Number of Vaccines Delayed.” Journal of the American Medical Association 293(10):1204–1211.CrossRefGoogle ScholarPubMed
Lurie, N., Manning, W.G., Peterson, C., et al. 1987. “Preventive Care: Do We Practice What We Preach?” American Journal of Public Health 77: 801–804.CrossRefGoogle ScholarPubMed
Mackenbach, J.P. 1991. “Health Care Expenditure and Mortality from Amenable Conditions in the European Community.” Health Policy 19: 245–255.CrossRefGoogle ScholarPubMed
Manca, A., Lambert, P., Hahn, S., Sculpher, M.J., and Rice, N.. 2004. “Exploring the Generalisability by Location of Multilevel Trial-Based CEA Results: The Case of Bayesian Hierarchical Linear Modeling,” in 5th European Conference of Health Economics, 542. London: Open Mind Journals.Google Scholar
Mansfield, Edwin. 1977. The Production and Application of New Industrial Technology. New York: W.W. Norton.Google Scholar
Mansfield, Edwin. 1986. “Patents and Innovation: An Empirical Study.” Management Science 32(2):173–181.CrossRefGoogle Scholar
Masson, A., and R. Steiner. 1985. “Generic Substitution and Prescription Drug Prices: Economic Effects of State Drug Product Selection Laws.” Staff Report of the Bureau of Economics, FTC, Washington, DC, October.
Maurer, S. 2005. “The Right Tool(s): Designing Cost-Effective Strategies for Neglected Disease Research.” Geneva: WHO Commission on Intellectual Property Rights, Innovation, and Public Health. Available at www.who.int/intellectualproperty/studies/research_development/en/.
Maurer, S., Rai, A., and Sali, A.. 2004. “Finding Cures For Tropical Diseases: Is Open Source an Answer?” PLOS: Medicine 1: 183–186. Available at http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0010056.Google ScholarPubMed
Maurer, S., and Scotchmer, S.. 2004. “Procuring Knowledge,” in Advances in the Study of Entrepreneurship, Innovation and Growth, ed. by G. Libecap, 15:1–31. Greenwich, CT: JAI Press.Google Scholar
McCarran, E. 1991. “Rx to OTC Switches: Promises and Pitfalls.” Medical Marketing and Media13–26.Google Scholar
McGuire, T.G. 2003. “Setting Prices for New Vaccines (in Advance).” International Journal of Health Care Finance and Economics 3(3):207–224.CrossRefGoogle Scholar
Megginson, William L., and Netter, Jeffry M.. 2001. “From State to Market: A Survey of Empirical Studies on Privatization.” Journal of Economic Literature 39(2):321–389.CrossRefGoogle Scholar
Meltzer, M.I., Cox, N.J., and Fukuda, K.. 1999. “The Economic Impact of Pandemic Influenza in the United States: Priorities for Intervention.” Emerging Infectious Disease 5(5):659–671.CrossRefGoogle ScholarPubMed
, Menzin J, Oster, G., Davies, L., Drummond, M.F., Greiner, W., Lucioni, C., Merot, J.L., Rossi, F., Schulenberg, V.D., and Souetre, E.. 1996. “A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis.” International Journal of Technology Assessment in Health Care 12(1):52–61.Google Scholar
Merrill, S.A., Levin, R.C., and Myers, M.B.. 2004. A Patent System for the 21st Century. Washington, DC: National Academies Press.Google Scholar
Millenson, Michael L. 2004. “Getting Doctors to Say Yes to Drugs: The Cost and Quality Impact of Drug Company Marketing to Physicians.” Chicago: Blue Cross Blue Shield Association. Available at www.bcbs.com/coststudies/reports/Drug_Co_Marketing_Report.pdf. Last accessed November 20, 2005.
Miller, Richard D., Jr., and Frech, H. E. III. 2004. Health Care Matters: Pharmaceuticals, Obesity, and the Quality of Life. Washington, DC: AEI Press.Google Scholar
Mitchell, V.S., Philipose, N.M., and Sanford, J.P., eds. 1993. The Children's Vaccine Initiative: Achieving the Vision. Washington, DC: National Academy Press.Google Scholar
Morgan, Steven G. 2002. “Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan.” Health Services Research 37: 1243–1266.CrossRefGoogle ScholarPubMed
Mueller, D. 1986. The Persistence of Profits. Cambridge: Cambridge University Press.Google Scholar
Murphy, Kevin, and Topel, Robert H.. 2003a. “The Economic Value of Medical Research,” in Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 41–73. Chicago: University of Chicago Press.CrossRefGoogle Scholar
Murphy, Kevin M., and Topel, Robert H.. 2003b. Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL: University of Chicago Press.CrossRefGoogle Scholar
Murphy, Kevin M., and Robert H. Topel. 2005. “The Value of Health and Longevity.” University of Chicago Working Paper.
Myers, Stewart. 1999. “Measuring Pharmaceutical Risk and the Cost of Capital,” in Risk and Return in the Pharmaceutical Industry, ed. by Jon Sussex and Nick Marchant, 59–76. London: Office of Health Economics.Google Scholar
Nace, N., Larson, C., Lester, T., and Kosinski, J.. 1999. “Perceived Barriers to Childhood Immunization: A Physician and Parent Survey in a Southeastern Urban/Rural Community.” Tennessee Medicine 92(7):265–268.Google Scholar
National Association of Boards of Pharmacy. 2004. Survey of Pharmacy Law for 2003–2004. Park Ridge, IL: NABC.
National Institute for Clinical Excellence (NICE). 2000. “Guidance on the Use of Zanamivir (Relenza) in the Treatment of Influenza.” Technology Appraisal Guidance No. 15. London: NICE.
National Institute for Clinical Excellence (NICE). 2004. Guide to the Methods of Technology Appraisal. London: NICE.
National Science Council (Taiwan). 2004. Indicators of Science and Technology. Taipei: NSC.
National Science Foundation. 2006. “National Expenditures for R&D, from Funding Sectors to Performing Sectors.” Available at www.nsf.gov/sbe/srs/nsf03313/tables/tab1b.xls.
Nelson, Philip K. 1970. “Information and Consumer Behavior.” Journal of Political Economy 78(2):311–329.CrossRefGoogle Scholar
Nelson, Philip K. 1974. “Advertising as Information.” Journal of Political Economy 82(4):729–754.CrossRefGoogle Scholar
Neslin, Scott A. 2001. ROI Analysis of Pharmaceutical Promotion (RAPPP). Unpublished study, Hanover, NH, Amos Tuck School of Business, Dartmouth College. Available at www.rxpromoroi.org/rapp.
Neumann, P.J. 2004. “Why Don't Americans Use Cost-Effectiveness Analysis?” American Journal of Managed Care 10: 308–312.Google ScholarPubMed
Newhouse, Joseph P. 2004. “How Much Should Medicare Pay for Drugs?” Health Affairs 23(1):89–102.CrossRefGoogle Scholar
New Zealand Ministry of Health. 2000a. “Direct to Consumer Advertising of Prescription Medicines under Review.” Media release, December 1. Available at www.moh.govt.nz/moh.nsf. Last accessed April 30, 2005.
New Zealand Ministry of Health. 2000b. “Direct-to-Consumer Advertising of Prescription Medicines in New Zealand: A Discussion Paper.” November. Available as dtcaDiscussionDoc.pdf at www.moh.govt.nz/moh.nsf. Last accessed April 30, 2005.
Nexoe, J., Kragstrup, J., and Ronne, T.. 1997. “Impact of Postal Invitations and User Fee on Influenza Vaccination Rates among the Elderly: A Randomized Controlled Trial in General Practice.” Scandinavian Journal of Primary Health Care 15(2):109–112.CrossRefGoogle ScholarPubMed
Nicholson, S., Patricia M. Danzon, and Geoffrey McCullough. 2002. “Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality.” National Bureau of Economic Research Working Paper 9007.
Nordhaus, William D. 2003. “The Health of Nations: The Contribution of Improved Health to Living Standards,” in Measuring the Gains from Medical Research: An Economic Approach,” ed. by Kevin M. Murphy and Robert H. Topel, 9–40. Chicago: University of Chicago Press.Google Scholar
Oeppen, J., and Vaupel, J.W.. 2002. “Demography: Broken Limits to Life Expectancy.” Science 296(5570):1029–1031.CrossRefGoogle ScholarPubMed
Offit, P.A. 2005. “Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?” Health Affairs 24(3):622–30.CrossRefGoogle ScholarPubMed
Ohmit, S.E., Furumotodawson, A., Monto, A.S., and Fasano, N.. 1995. “Influenza Vaccine Use among an Elderly Population in a Community Intervention.” American Journal of Preventive Medicine 11(4):271–276.CrossRefGoogle Scholar
Or, Zeynep. 2003. “Determinants of Health Outcomes in Industrialised Countries: A Pooled, Cross-Country, Time-Series Analysis.” OECD Economic Studies No. 30, 2000/I. Available at www.oecd.org.
Organization for Economic Cooperation and Development. 2004. “Table 1. Life Expectancy in Years,” in OECD Health Data 2004, 3rd ed. Available at www.oecd.org.
Outterson, Kevin. 2004. “The U.S.-Australian Free Trade Agreement's Unfortunate Attack and Good Healthcare Policy.” Comments Submitted to the U.S. Congress, House of Representatives, Committee on Ways and Means, June 22, 2004. Available at www.ita.doc.gov/td/chemicals/phRMA/Outterson%20Response1.pdf. Last accessed October 20, 2005.
Padden, Michael, and Jenkins, Thomas. 2004. “Hatch-Waxman Changes.” National Law Journal, February 23, p. 13.Google Scholar
Palda, Kristian. 1969. Economic Analysis for Marketing Decisions. New York: Prentice-Hall.Google Scholar
Palmer, S., Sculpher, M., Philips, M. Robinson, Ginnelly, L., and Gary, D.. 2005. “Management of Non-ST-Elevation Acute Coronary Syndromes: How Cost-Effective Are Glycoprotein IIb/IIIa Antagonists in the UK National Health Service?” International Journal of Cardiology 100(2):229–240.CrossRefGoogle ScholarPubMed
Pauly, M.V. 1998. Health Benefits at Work: An Economic and Political Analysis of Employment-Based Health Insurance. Ann Arbor: University of Michigan Press.CrossRefGoogle Scholar
Pauly, M.V. 2005. “Improving Vaccine Supply And Development: Who Needs What?” Health Affairs 24(3):680–689.CrossRefGoogle Scholar
Pauly, M.V., Danzon, P., Feldstein, P., and Hoff, J.. 1991. “A Plan for ‘Responsible National Health Insurance.’” Health Affairs 10(1):5–25.CrossRefGoogle Scholar
Pharmaceutical R&D Policy Project. 2005. “The New Landscape of Neglected Disease Drug Development.” London: London School of Economics. Available at www.lse.ac.uk/collections/pressAndInformationOffice/PDF/Neglected_Diseases_05.pdf.
Pharmaceutical Research and Manufacturers of America. 2000. Pharmaceutical Industry Profile. Washington, DC: Pharmaceutical Research and Manufacturing Association.
Pharmaceutical Research and Manufacturers of America. 2005. PhRMA Guiding Principles: Direct to Consumer Advertisements about Prescription Medicines. Washington, DC, August 2005. Available at www.phrma.org.
Philipson, T. 2000. “Economic Epidemiology and Infectious Diseases,” in Handbook of Health Economics, ed. by A.J. Culyer and J.P. Newhouse, 1B: 1761–1769. Amsterdam: Elsevier Science.Google Scholar
Pines, Wayne L. 1999. “A History and Perspective on Direct-to-Consumer Promotion.” Food and Drug Law Journal 54: 489–518.Google ScholarPubMed
Pleis, J., and Gentleman, J.. 2002. “Using the National Health Interview Survey: Time Trends in Influenza Vaccinations among Targeted Adults.” Effective Clinical Practices 5(3 Suppl.):E3.Google ScholarPubMed
Plotkin, S.A. 2005. “Why Certain Vaccines Have Been Delayed or Not Developed at All.” Health Affairs 24(3):631–634.CrossRefGoogle ScholarPubMed
Pogge, T. 2005. “Human Rights and Global Health: A Research Program.” Metaphilosophy 36(1/2):182–209.CrossRefGoogle Scholar
Poikoilainen, K., and Eskola, J.. 1988. “Health Services Resources and Their Relation to Mortality from Causes Amenable to Health Care Intervention: A Cross-national Study.” International Journal of Epidemiology 17(1):86–89.CrossRefGoogle Scholar
Pomerantz, Jay M., Finkelstein, Stan N., Berndt, Ernst R., Poret, Amy W., Walker, Leon E., Alber, Robert C., Kadiyam, Vidya, Das, Mitali, Boss, David T., and Ebert, Thomas H.. 2004. “Prescriber Intent, Off-Label Usage, and Early Discontinuation of Antidepressants.” Journal of Clinical Psychiatry 65(3):395–404.CrossRefGoogle ScholarPubMed
Popp, David. 2001. “Induced Innovation and Energy Prices.” National Bureau of Economic Research Working Paper 8284.
Poulson, David, and Sarah Kellogg. “Private Labs' Ability to Deliver Vaccines Questioned.” Available at www.newhouse.com/archive/story1c110501.html.
Rappuoli, Rino, Miller, Henry I., and Falkow, Stanley. 2002. “The Intangible Value of Vaccination.” Science 297(5583):937–938.CrossRefGoogle ScholarPubMed
Rawlins, M.D., and Culyer, A.J.. 2004. “National Institute for Clinical Excellence and Its Value Judgments.” British Medical Journal 329: 224–227.CrossRefGoogle ScholarPubMed
Reichert, T.A., Sugaya, N., Fedson, D.S., et al. 2001. “The Japanese Experience with Vaccinating Schoolchildren against Influenza.” New England Journal of Medicine 344(12):889–896.CrossRefGoogle ScholarPubMed
Reiffen, David, and Ward, Michael R.. 2005. “Generic Drug Industry Dynamics.” Review of Economics and Statistics 87(1):37–49.CrossRefGoogle Scholar
Reiffen, David, and Ward, Michael. 2006. “Branded Generics as a Strategy to Limit Cannibalization of Pharmaceutical Markets.” Managerial and Decision Economics, forthcoming.Google Scholar
Reinhardt, Uwe E. 1996. “Rationing in Health Care: What It Is, What It Is Not, and Why We Cannot Avoid It,” in Strategic Choices for a Changing Health System, ed. by Stuart H. Altman and E. Uwe, 63–100. Chicago: Health Administration Press.Google Scholar
Reinhardt, Uwe E. 1997. “Making Economic Evaluations More Respectable.” Social Science and Medicine 45(4):555–562.CrossRefGoogle ScholarPubMed
Reinhardt, Uwe E. 2001. “Can Efficiency in Health Care Be Left to the Market?” Journal of Health Politics, Policy and Law 26(5):967–992.CrossRefGoogle Scholar
Reinhardt, Uwe E. 2004. “An Information Infrastructure for the Pharmaceutical Market.” Health Affairs 23(1):107–112.CrossRefGoogle ScholarPubMed
Rice, Thomas H. 2002. The Economics of Health Reconsidered. Chicago: Health Administration Press.Google Scholar
Ridley, R.G. 2004. “Product Development Public-Private Partnerships for Diseases of Poverty,” in Combating Diseases Associated with Poverty, ed. by R. Widdus and K. White. Geneva: Initiative on Public-Private Partnerships for Health.Google Scholar
Riordan, M.H., and Sappington, D.E.M.. 1989. “Second Sourcing.” Rand Journal of Economics 20(1):41–58.CrossRefGoogle Scholar
ROC Department of Health. 2005. Health and Vital Statistical. Taipei: Department of Health.
Rodewald, L., Maes, E., Stevenson, J., et al. 1999. “Immunization Performance Measurement in a Changing Immunization Environment.” Pediatrics 103(4):889–897.Google Scholar
Rogerson, W.P. 1989. “Profit Regulation of Defense Contractors and Prizes for Innovation.” Journal of Political Economy 97(6):1284–1305.CrossRefGoogle Scholar
Rogerson, W.P. 1994. “Economic Incentives and the Defense Procurement Process.” Journal of Economic Perspectives 8(4):65–90.CrossRefGoogle Scholar
Romer, Paul. 1990. “Endogenous Technological Change.” Journal of Political Economy 98: 71–102.CrossRefGoogle Scholar
Rosenthal, Meredith B., Berndt, Ernst R., Donohue, Julie M., Epstein, Arnold M., and Frank, Richard G.. 2003. “Demand Effects of Recent Changes in Prescription Drug Promotion,” chapter 1 in Frontiers in Health Policy Research, vol. 6, ed. Alan M. Garber, 1–26. Cambridge, MA: MIT Press for the National Bureau of Economic Research.Google Scholar
Rosenthal, Meredith B., Berndt, Ernst R., Donohue, Julie M., Frank, Richard G., and Epstein, Arnold M.. 2002. “Promotion of Prescription Drugs to Consumers.” New England Journal of Medicine 346(7):498–505.CrossRefGoogle Scholar
Rosso, R. 2001. “Trends in Food Stamp Program Participation Rates: 1994 to 1999.” Alexandria, VA: United States Department of Agriculture, Food and Nutrition Service.
Rubin, Robert, Hawk, Ann, and Cascade, Elisa. 1998. “PBMs: A Purchaser's Perspective,” in PBMs: Reshaping the Pharmaceutical Distribution Network, ed. by Sheila Shulman, Elaine Healy, and Louis Lasagna, 30. Binghamton, NY: Pharmaceutical Products Press.Google Scholar
Saha, Atanu, Grabowski, Henry, Birnbaum, Howard, Greenberg, Paul, and Bizan, Oded. 2006. “Generic Competition in the U.S. Pharmaceutical Industry.” International Journal of the Economics of Business 13(1):15–38.CrossRefGoogle Scholar
Salkever, D., and Frank, R.. 1996. “Economic Issues in Vaccine Purchase Agreements,” in Supplying Vaccine: An Economic Analysis of Critical Issues, ed. by M. Pauly, C.A. Robinson, S. Sepe, M. Sing, and M.K. Willian. Amsterdam: IOS Press.Google Scholar
Satterthwaite, P. 1997. “A Randomised Intervention Study to Examine the Effect on Immunisation Coverage of Making Influenza Vaccine Available at No Cost.” New Zealand Medical Journal 110(1038):58–60.Google ScholarPubMed
Saunders, Barrie. 2003. “Direct to Consumer Advertising of Prescription Drugs in New Zealand: Professors' Protest to Government Placed under the Microscope.” Wellington, New Zealand: Saunders Unsworth. Available at www.sul.co.nz.
Scharfstein, D. 1988. “The Disciplinary Role of Takeovers.” Review of Economic Studies 55(2):185–199.CrossRefGoogle Scholar
Scherer, F.M. 2000. “The Pharmaceutical Industry,” in Handbook of Health Economics, vol. 1, ed. by A.J. Culyer and J.P. Newhouse, 297–336. Amsterdam: Elsevier Science.Google Scholar
Scherer, F.M. 2001. “The Link between Gross Profitability and Pharmaceutical R&D Spending.” Health Affairs 20: 216–220.CrossRefGoogle ScholarPubMed
Scherer, F.M., and Ross, D.R.. 1990. Industrial Market Structure and Economic Performance. 3rd ed. Boston: Houghton-Mifflin.Google Scholar
Schmalensee, R. 1979. The Control of National Monopolies. Lexington, MA: D.C. Heath, Lexington Books.Google Scholar
Schmookler, Jacob. 1966. Invention and Economic Growth. Cambridge, MA: Harvard University Press.CrossRefGoogle Scholar
Schwartzman, David, and Cognato, Antonio. 1996. “Has Pharmaceutical Research Become More Scientific?” Review of Industrial Organization 11: 841–851.CrossRefGoogle Scholar
Schweitzer, Stuart. 1997. Pharmaceuticals, Economics, and Policy. New York: Oxford University Press.Google Scholar
Scotchmer, S. 2004. Innovation and Incentives. Cambridge, MA: MIT Press.Google Scholar
Scott Morton, F.M. 1999. “Entry Decisions in the Generic Pharmaceutical Industry.” RAND Journal of Economics 30(3):421–440.CrossRefGoogle Scholar
Scott Morton, F.M. 2000. “Barriers to Entry Brand Advertising, and Generic Entry in the U.S. Pharmaceutical Industry.” International Journal of Industrial Organization 18(7):1085–1104.CrossRefGoogle Scholar
Scriabiane, Alexander. 1999. “The Role of Biotechnology in Drug Development,” in Pharmaceutical Innovation: Revolutionizing Human Health, ed. by Ralph Landau, Basil Achilladelis, and Alexander Scriabine. Philadelphia: Chemical Heritage Foundation Press.Google Scholar
Sculpher, M.J., Pang, F.S., Manca, A., Drummond, M.F., Golder, S., Urdahl, H., Davies, L.M., and Eastwood, A.. 2004. Generalisability in Economic Evaluation Studies in Health Care: A Review and Case Studies. Health Technology Assessment 8(49) (whole issue).CrossRefGoogle Scholar
Shavell, S., and Ypersele, T.. 2001. “Rewards versus Intellectual Property Rights.” Journal of Law and Economics 44(2):525–547.CrossRefGoogle Scholar
Shaw, James W., Horrace, William C., and Vogel, Ronald J.. 2005. “The Determinants of Life Expectancy: An Analysis of the OECD Health Data.” Southern Economic Journal 71(4):768–783.CrossRefGoogle Scholar
Shleifer, Andrei. 1998. “State versus Private Ownership.” Journal of Economic Perspectives 12(4):133–150.CrossRefGoogle Scholar
Shleifer, A., and Vishny, R.. 1994. “Politicians and Firms.” Quarterly Journal of Economics 109: 995–1025.CrossRefGoogle Scholar
Siegel, Jonathan B. 2004. “Financial Aspects of 180-Day Generic Exclusivity.” Presentation to the Food and Drug Law Institute Conference on Two Decades of Hatch-Waxman, December 1–2, Washington, DC.
Sinclair, G., Klepper, S., and Cohen, W.. 2000. “What's Experience Got to Do with It? Sources of Cost Reduction in a Large Specialty Chemicals Producer.” Management Science 46(1):25–28.CrossRefGoogle Scholar
Skinner, J., and Wennberg, J.E.. 2000. “How Much Is Enough? Efficiency and Medicare Spending in the Last Six Months of Life,” in The Changing Hospital Industry: Comparing Not-for-Profit and For-Profit Institutions, ed. by David Cutler, 169–193. Chicago: University of Chicago Press.Google Scholar
Sloan, Frank A., and Conover, Chris J.. 1998. “Effects of State Reforms on Health Insurance Coverage of Adults.” Inquiry 35: 280–293.Google ScholarPubMed
Sloan, Frank A., and Grabowski, Henry G.. 1997. “Introduction and Overview.” Social Science and Medicine 54(4):505–510.CrossRefGoogle Scholar
Sloan, Frank A., Whetten-Goldstein, K., and Wilson, A.. 1997. “Hospital Pharmacy Decisions, Cost Containment, and the Use of Cost-Effectiveness Analysis.” Social Science and Medicine 54(4):525–536.Google Scholar
Smith, J.S. 1990. Patenting the Sun. New York: Morrow.Google Scholar
Song, F., Altman, D.G., Glenny, A.M., and Deeks, J.. 2003. “Validity of Indirect Comparison for Estimating Efficacy of Competing Interventions: Empirical Evidence from Published Meta-Analyses.” British Medical Journal 326: 472–478.CrossRefGoogle ScholarPubMed
Sorenson, Alan T. 2000. “Equilibrium Price Dispersion in Retail Markets for Prescription Drugs.” Journal of Political Economy 108(4):833–850.CrossRefGoogle Scholar
Spence, M. 1984. “Cost Reduction, Competition, and Industry Performance.” Econometrica 52: 101–121.CrossRefGoogle Scholar
Spulber, D. 1989. Regulation and Markets.Cambridge, MA: MIT Press.Google Scholar
Stapleton, S. 2004. “Project BioShield.” American Medical News 47(31):19.Google Scholar
Canada, Statistics. 1974. Life Tables, Canada and Provinces, 1970–1972. Ottawa: Minister of Industry.Google Scholar
Canada, Statistics. 2002. Life Tables, Canada, Provinces and Territories, 1995–1997. Ottawa: Minister of Industry.Google Scholar
Stein, J.C. 1988. “Takeover Threats and Managerial Myopia.” Journal of Political Economy 96(1):61–80.CrossRefGoogle Scholar
Stern, Scott, Michael E. Porter, and Jeffrey L. Furman. 2000. “The Determinants of National Innovative Capacity.” National Bureau of Economics Research Working Paper 7876.
Stinnett, A.A., et al. 1996. “The Cost Effectiveness of Dietary and Pharmacologic Therapy for Cholesterol Reduction in Adults,” in Cost Effectiveness in Health and Medicine, ed. by M. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein, 349–391. Oxford: Oxford University Press.Google Scholar
Stratton, K.R., Durch, J.S., and Lawrence, R.S.. 2000. Vaccines for the 21st Century: A Tool for Decision-Making. Washington, DC: Institute of Medicine, National Academy Press.Google Scholar
Summers, L.H. 1989. “What Can Economics Contribute to Social Policy?” American Economic Review 79(2):177–183.Google Scholar
Tan, Litjen, and the American Medical Association, . 2006. “Strengthening the Supply of Routinely Recommended Vaccines in the United States: A Perspective from the American Medical Association.” Clinical Infectious Diseases 42(Suppl. 3): S121–S124.CrossRefGoogle ScholarPubMed
Taylor, C.R. 1995. “Digging for Golden Carrots: An Analysis of Research Tournaments.” American Economic Review 85(4):872–890.Google Scholar
Temin, Peter. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press.CrossRefGoogle Scholar
Thomas, P. 2002. “The Economics of Vaccines.” Harvard Medical International (HMI) World, September/October.Google Scholar
Tobin, James. 1969. “A General Equilibrium Approach to Monetary Theory.” Journal of Money, Credit, and Banking 1(1):15–29.CrossRefGoogle Scholar
Toop, Les, Dee Richards, Tony Dowell, Murray Tilyard, Tony Fraser, and Bruce Arrol. 2003. “Direct to Consumer Advertising of Prescription Drugs in New Zealand: For Health or for Profit?” Report to the Minister of Health Supporting the Case for a Ban on DTCA, February. Available at www.chmeds.ac.nz/report.pdf. Last accessed April 30, 2005.
Towse, A. 2004. “Developing the Idea of Transferable Intellectual Property Rights (TIPP) to Incentivize R&D in Drugs and Vaccines for Neglected Diseases.” Office of Health Economics, London, March 2, Appendix I, 22–24.
Towse, A., and H. Kettler. 2005. “Review of IP and Non-IP Incentives for R&D for Diseases of Poverty: What Type of Innovation Is Required and How Can We Incentivise the Private Sector to Deliver It?” Available at www.who.int/intellectualproperty/studies/health_innovation/en. Last accessed May 10, 2005.
Towse, A., Mestre-Fernandez, J., and Renowden, O.. 2004. “Estimates of the Medium Term Financial Resource Needs for Development of Pharmaceuticals to Combat ‘Neglected Diseases,’” in Combating Diseases Associated with Poverty, ed. by R. Widdus and K. White. Geneva: Initiative on Public-Private Partnerships for Health.Google Scholar
Tufts Center for the Study of Drug Development. 2003. “Total Cost to Develop a New Prescription Drug, Including Cost of Post-Approval Research, Is $897 million.” Press release, May 13, 2003. Available at www.csdd.tufts.edu.
Turner, Margaret A. 2003. “Strengths and Weaknesses of the Housing Voucher Program.” Congressional Testimony prepared for the Committee on Financial Services, Subcommittee on Housing and Community Opportunity, U.S. House of Representatives, June 17, 2003. Available at www.urban.org/url.cfm?ID=900635.
U.S. Centers for Disease Control and Prevention. 1999. “An Ounce of Prevention … What Are the Returns?” 2nd ed. Available at www.cdc.gov/epo/prevent.htm.
U.S. Centers for Disease Control and Prevention. 2002a. “Influenza and Pneumococcal Vaccination Levels among Persons Aged > 65 years, United States, 2001.” Morbidity and Mortality Weekly Report 51(45):1019–1024.
U.S. Centers for Disease Control and Prevention. 2002b. “National, State, and Urban Area Vaccination Coverage Levels among Children Aged 19–35 Months: United States, 2001.” Morbidity and Mortality Weekly Report 3: 664–666.
U.S. Centers for Disease Control and Prevention. 2003. “National, State, and Urban Area Vaccination Coverage Levels among Children Aged 19–35 Months: United States, 2002.” Morbidity and Mortality Weekly Report 52(31):728–732.
U.S. Centers for Disease Control and Prevention. 2004. “Influenza Viruses.” Available at www.cdc.gov/flu/avian/gen-info/flu-viruses.htm. Last accessed March 2, 2005.
U.S. Centers for Disease Control and Prevention. 2005a. “Influenza Pandemics.” Available at www.cdc.gov/flu/avian/gen-info/pandemics.htm. Last accessed March 2, 2005.
U.S. Centers for Disease Control and Prevention. 2005b. “Avian Influenza Infection in Humans.” Available at www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm. Last accessed March 2, 2005.
U.S. Centers for Medicaid and Medicare Services. 2003. “The Nation's Health Care Dollar: 2001.” Washington, DC: Government Printing Office.
U.S. Committee on Ways and Means, U.S. House of Representatives. 2003. Background Material and Data on the Programs within the Jurisdiction of the Committee on Ways and Means. (Informally known as the “Green Book.”) WMCP 108–6. Washington, DC: Government Printing Office.
U.S. Congressional Budget Office. 1998. “How Increased Competition Has Affected Prices and Returns in the Pharmaceutical Industry.” July, 38. Washington, DC: Government Printing Office.
U.S. Department of Health and Human Services. 2002. “Payment by Results” Breakthrough Ends Years of Uncertainty for MS Patients: Agreement Follows Recommendation from NICE. Washington, DC: Government Printing Office.
U.S. Department of Health and Human Services. 2004. “Pandemic Influenza Preparedness and Response Plan,” 1–54. Washington, DC: Government Printing Office.
U.S. Food and Drug Administration. 1999. “Creating a Risk Management Framework: Report to the FDA Commissioner from the Task Force on Risk Management.” Washington, DC: Government Printing Office.
U.S. Food and Drug Administration. 2005. “CDER NDAs Approved in Calendar Years 1990–2204 by Therapeutic Potential and Chemical Type.” Available at www.fda.gov/cder/rdmt/pstable.htm.
U.S. Senate. 1960–. Administered Prices in the Drug Industry. Hearings before the Sub-Committee on Antitrust and Monopoly, 86th Congress, 1959 and 1960, Part 18. Washington, DC: Government Printing Office.
U.S. Senate, Republican Policy Committee. 2005. “Pharmaceutical Price Controls Abroad: An Unfair Trade Policy.” Available at www.kyl.senate.gov/legis_center/rpc_110603.pdf. Last accessed October 20, 2005.
Vernon, John M. 1981. “Concentration, Promotion, and Market Share Stability in the Pharmaceutical Industry.” Journal of Industrial Economics 19(3):246–266.CrossRefGoogle Scholar
Vernon, J., and Grabowski, H.. 2000. “The Distribution of Sales Revenues from Pharmaceutical Innovation.” PharmoEconomics 18(1):21–32.Google Scholar
Vernon, John M., and Gusen, Peter. 1974. “Technical Change and Firm Size: Pharmaceutical Industry.” Review of Economics and Statistics 56: 294–302.CrossRefGoogle Scholar
Viscusi, W. Kip. 1993. “The Value of Risks to Life and Health.” Journal of Economic Literature 31: 1912–1946.Google Scholar
Viscusi, W. Kip. 1995. “Discounting Health Effects for Medical Decisions,” in Valuing Health Care, ed. Frank Sloan, 125–147. Cambridge: Cambridge University Press.Google Scholar
Viscusi, W. Kip, and Aldy, Joseph E.. 2003. “The Value of a Statistical Life: A Critical Review of Market Estimates throughout the World.” Journal of Risk and Uncertainty 27(1):5–76.CrossRefGoogle Scholar
Vistnes, G. 1994. “An Empirical Investigation of Procurement Contract Structures.” Rand Journal of Economics 25(2):215–241.CrossRefGoogle ScholarPubMed
Walsh, J.P., Arora, A., and Cohen, W.M.. 2003. “Working through the Patent Problem.” Science 299(5609):1021.CrossRefGoogle ScholarPubMed
Weissman, Joel S., Blumenthal, David, Silk, Alvin J., Newman, Michael, Zapert, Kinga, Leitman, Robert, and Feibelmann, Sandra. 2004. “Physicians Report on Patient Encounters Involving Direct-to-Consumer Advertising.” Health Affairs – Web Exclusive W4: 219–233.Google Scholar
WHO. 2004. World Health Report, Revised Global Burden of Disease 2002 Estimates. London: WHO.
WHO Collaborating Centre for Drug Statistics Methodology. 2004. “Guidelines for ATC Classification and DDD Assignment.” Oslo: Norwegian Institute.
Widdus, Roy, and Katherine White. 2004. “Combating Diseases of Poverty: Financing Strategies for Product Development and the Potential Role of Private-Public Partnerships.” Geneva: Initiative on Private-Public Partnerships for Health.
Wilby, J., Kainth, A., Hawkins, N., Epstein, D., McDaid, C., et al. 2003. A Rapid and Systematic Review of the Clinical Effectiveness, Tolerability and Cost-Effectiveness of Newer Drugs for Epilepsy in Adults. Report to the National Institute for Clinical Excellence, forthcoming.Google Scholar
Willan, A.R., Pinto, E.M., O'Brien, B.J., et al. 2005. “Country Specific Cost Comparisons from Multinational Clinical Trials Using Empirical Bayesian Shrinkage Estimation: The Canadian ASSENT-3 Economic Analysis.” Health Economics 14(1):327–338.CrossRefGoogle ScholarPubMed
Wittink, Richard R. 2002. “Analysis of ROI for Pharmaceutical Promotions,” September, video presentation, Association of Medical Publications. Available at www.vioworks.com/clients/amp.
Wosinska, Marta. 2002. “Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products.” Harvard Business School, Marketing Research Paper Series, No. 02-04.
Wosinska, Marta. 2005. “Direct-to-Consumer Advertising and Drug Therapy Compliance.” Journal of Marketing Research 42(3):323–332.CrossRefGoogle Scholar
Wright, Brian D. 1983. “The Economics of Invention Incentives: Patents, Prizes, and Research Contracts.” American Economic Review 73: 691–707.Google Scholar
Zucker, Lynne E., Darby, Michael R., and Brewer, Marilynn B.. 1998. “Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises.” American Economic Review 88(1):290–306.Google Scholar
Abramocicz, M. 2003. “Perfecting Patient Prizes.” Vanderbilt Law Review 56(1):114–236.Google Scholar
Acemoglu, D., and Linn, J.. 2004. “Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry.” Quarterly Journal of Economics 119(3):1049–1090.CrossRefGoogle Scholar
Ackerberg, D. 2003. “Advertising, Learning, and Consumer Choice in Experience Good Market: A Structure Examination.” International Economic Review 44: 1007–1040.CrossRefGoogle Scholar
Addis, A., and Magrini, N.. 2002. “New Approaches to Analysing Prescription Data and Transfer Pharmacoepidemiological and Evidence-Based Reports to Prescribers.” Pharmacoepidemiology and Drug Safety 11: 721–726.CrossRefGoogle ScholarPubMed
Ades, A. 2003. “A Chain of Evidence with Mixed Comparisons: Models for Multi-parameter Syntheses and Consistency of Evidence.” Statistics in Medicine 22: 2995–3016.CrossRefGoogle Scholar
Advanced Markets Working Group. 2005. Making Markets for Vaccines: A Practical Plan to Spark Innovation for Global Health. Washington, DC: Center for Global Development & Global Health Policy Research Network. Available at www.cgdev.org/section/initiatives/_active/vaccinedevelopment/chapters.
Aghion, Philippe, and Tirole, Jean. 1994. “The Management of Innovation.” Quarterly Journal of Economics 109: 1185–1209.CrossRefGoogle Scholar
Aikin, Kathryn J. 2003. “The Impact of Direct-to-Consumer Prescription Drug Advertising on the Physician-Patient Relationship.” PowerPoint presentation. Available at www.fda.gov/cder/ddmac/aikin/sld001.htm.
Almond, D. 2003. “Is the 1918 Influenza Pandemic Over? Long-Term Effects of Utero Influenza Exposure in the Post-1940 U.S. Population.” Available at www.nber.org/∼almond. Last accessed January 21, 2005.
American Psychiatric Association. 2003. Practice Guidelines for the Treatment of Patients with Major Depression. Available at www.psych.org/psych_pract/treatg/pg/Depression2e.book.cfm. Last accessed July 18, 2004.
Anand, G. 2004. “How Drug's Rebirth as Treatment for Cancer Fueled Price Rises; Once-Demonized Thalidomide Boosts Celgene's Sales; Patients See Costs Soar; Avoiding AIDS Activists.” Wall Street Journal, November 15, 2004.Google Scholar
Anderson, G.F., and Hussey, P.S.. 2001. “Comparing Health System Performance in OECD Countries.” Health Affairs 20(5):219–232.CrossRefGoogle ScholarPubMed
Anderson, G.F., Reinhardt, U.E., Hussey, P.S., and Petrosyan, Varduhi. 2003. “It's the Prices, Stupid: Why the United States Is So Different from Other Countries.” Health Affairs 22(3):89–105.CrossRefGoogle ScholarPubMed
Angell, Marcia. 2004. The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York: Random House.Google Scholar
Anis, A.H., and Gagnon, Y.. 2000. “Using Economic Evaluations to Make Formulary Coverage Decisions: So Much for Guidelines.” PharmacoEconomics 18: 55–62.CrossRefGoogle ScholarPubMed
Anon, N.D. 2005. “The History of the Pasteur Institute.” Paris: Pasteur Institute. Available at www.pasteur.fr/english.html.
Anton, J.J., and Yao, D.A.. 1987. “Second Sourcing and the Experience Curve: Price Competition in Defense Procurement.” Rand Journal of Economics 18(1):57–76.CrossRefGoogle Scholar
Anton, J.J., and Yao, D.A.. 1989. “Split Awards, Procurement, and Innovation.” Rand Journal of Economics 20(4):538–552.CrossRefGoogle Scholar
Arnould, R., and L. DeBrock 2002. “An Overview of the Market for Vaccines in the United States.” Unpublished. Available from the Institute of Medicine, Washington, DC.
Arrow, Kenneth J. 1963. “Uncertainty and the Welfare Economics of Medical Care.” American Economic Review 53(5):941–973.Google Scholar
Avorn, Jerry. 2003. “Advertising and Prescription Drugs: Promotion, Education, and the Public Health.” Health Affairs – Web Exclusive W3: 104–108.Google Scholar
Avorn, Jerry. 2004. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Alfred A. Knopf.Google Scholar
Azoulay, Pierre. 2004. “Capturing Knowledge within and across Firm Boundaries: Evidence from Clinical Development.” American Economic Review 94 (5):1591–1612.CrossRefGoogle Scholar
Babazono, Akira, and Hillman, Alan L.. 1994. “A Comparison of International Health Outcomes and Health Care Spending.” International Journal of Technology Assessment in Health Care 10(3):376–381.CrossRefGoogle ScholarPubMed
Bagwell, Kyle, ed. 2001. The Economics of Advertising. International Library of Critical Writings in Economics, vol. 136. Cheltenham, U.K.: Edward Elgar Publishing.Google Scholar
Bain & Company. 2005. “The Pharma Innovation Divide: The High Cost of Europe's ‘Free Ride.’” Available at www.bain.com/bainweb/Consulting_Expertise/hot_topics/detail.asp?id=22. Last accessed October 28, 2005.
Baines, Darrin L, Tally, Keith H., and Whynes, David K.. 1997. Prescribing Budgets and Fundholding in General Practice. London: Office of Health Economics.Google Scholar
Batchlor, Elaine, and Laouri, Marianne. 2003. “Pharmaceutical Promotion, Advertising, and Consumers.” Health Affairs – Web Exclusive W3: 109–115.Google Scholar
Bear Stearns. 2002. “Attack of the Clones: 18 Years past Waxman-Hatch.” October 2. New York: Bear Stearns.
Becker, Elizabeth. 2003. “U.S. Is Battling for Higher Drug Prices Overseas.” New York Times, November 28.Google Scholar
Becker, Gary S., Phillipson, Thomas J., and Soares, Rodrigo R.. 2005. “The Quantity and Quality of Life and the Evolution of World Inequality.” American Economic Review 95(1):277–291.CrossRefGoogle ScholarPubMed
Benkler, Y. 2004. “Commons Based Strategies and the Problems of Patents.” Science 305: 1110–1111.CrossRefGoogle ScholarPubMed
Berndt, Ernst R. 2001. “The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?” Health Affairs 20(2):100–114.CrossRefGoogle ScholarPubMed
Berndt, E.R. 2002. “Pharmaceuticals in U.S. Health Care: Determinants of Quality and Price.” Journal of Economic Perspectives 16(4):45–66.CrossRefGoogle Scholar
Berndt, Ernst R. 2005. “To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs.” New England Journal of Medicine 352(4):325–328.CrossRefGoogle ScholarPubMed
Berndt, Ernst R., Bhattacharjya, Ashoke, Mishol, David, Arcelus, Almudena, and Lasky, Thomas. 2002. “An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts.” Journal of Mental Health Policy and Economics 5(1):3–17.Google ScholarPubMed
Berndt, Ernst R., Iain M. Cockburn, and Karen A. Grepin. 2005. “Biopharmaceutical R&D: Is the Productivity Decline Overstated?” Working paper, Conference on Health Reform in Europe and the U.S., Tufts Center, Talloues, France, July 2005.
Berndt, E., R. Glennerster, M.R. Kremer, J. Lee, R. Levine, G. Weizsacker, and H. Williams. 2005. “Advanced Markets for a Malaria Vaccine: Estimating Costs and Effectiveness.” National Bureau of Economic Research Working Paper 11288.
Berndt, E.R., and Hurwitz, J.A.. 2005. “Vaccine Advance Purchase Agreements for Low-Income Countries: Practical Issues.” Health Affairs 24(3):653–665.CrossRefGoogle ScholarPubMed
Berndt, Ernst R., Margaret K. Kyle, and Davina C. Ling. 2003. “The Long Shadow of Patent Expiration: Generic Entry and Rx to OTC Switches.” Chapter 8 in Scanner Data and Price Indexes, NBER Series on the Conference on Research in Income and Wealth, vol. 61, ed. by Feenstra, Robert C. and Shapiro, Matthew D., 229–267. Chicago: University of Chicago Press for the National Bureau of Economic Research.CrossRefGoogle Scholar
Beutels, P., Edmunds, W.J., Antoñanzas, F., Wit, G.A., Evans, D., Feilden, R., Fendrick, A.M., et al. 2002. “Economic Evaluation of Vaccination Programmes: A Consensus Statement Focusing on Viral Hepatitis.” PharmacoEconomics 20: 1–7.CrossRefGoogle ScholarPubMed
Birch, S., and Gafni, A.. 2002. “On Being NICE in the UK: Guidelines for Technology Appraisal for the NHS in England and Wales.” Health Economics 11: 185–191.CrossRefGoogle ScholarPubMed
Black, Douglas J., Smith, Cyril, and Townsend, Peter. 1982. Inequalities in Health: The Black Report. New York: Penguin Books.Google Scholar
Bloom, B.D.J. Wiertz, and Pauly, M.. 1986. “Cost and Price of Comparable Branded and Generic Pharmaceuticals.” Journal of the American Medical Association 256(18):2523–2530.CrossRefGoogle Scholar
Boardman, Anthony, Freedman, Ruth, and Eckel, Catherine. 1986. “The Price of Government Ownership: A Study of the Domtar Takeover.” Journal of Public Economics 31(3):269–286.CrossRefGoogle Scholar
Boardman, Anthony E., and Vining, Aidan R.. 1989. “Ownership and Performance in Competitive Environments: A Comparison of the Performance of Private, Mixed, and State-Owned Enterprises.” Journal of Law and Economics 32(1):1–33.CrossRefGoogle Scholar
Boswell, C. 2003. “InnoCentive and Web-Based Collaborative Innovation.” Chemical Market Reporter, April 14.Google Scholar
Bradford, D.F., and D.N. Shaviro. 2000. “The Economics of Vouchers,” in Vouchers and the Provision of Public Services, ed. by Steuerle, C.E., Ooms, Doorn, Peterson, George, and Reischauer, Robert D., 606–607. Washington, DC: Brookings Institution Press.Google Scholar
Branstetter, Lee G., Raymond Fisman, and C. Fritz Foley. 2003. “Do Stronger Intellectual Property Rights Increase International Technology Transfer? Empirical Evidence from U.S. Firm-Level Panel Data.” Unpublished paper, Columbia University Business School.
Breyer, S. 1982. Regulation and Its Reform. Cambridge, MA: Harvard University Press.Google Scholar
Brito, D.L., Sheshinski, E., and Intriligator, M.D.. 1991. “Externalities and Compulsory Vaccinations.” Journal of Public Economics 45: 69–90.CrossRefGoogle Scholar
Caffrey, Andrew. 2002. “Why Generics Can Cost States More Money.” Wall Street Journal, February 13.Google Scholar
Calfee, John E. 2002. “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs.” Journal of Public Policy & Marketing 21(2):174–193.CrossRefGoogle Scholar
Calfee, John E. 2003. “What Do We Know about Direct-to-Consumer Advertising of Prescription Drugs?” Health Affairs – Web Exclusive W3: 116–119.Google Scholar
Calfee, John E. 2004. “Paying for the Pills: How Much Does It Really Cost to Put a New Drug on the Market?” Nature 429: 807.CrossRefGoogle Scholar
Calfee, John E., Winston, Clifford, and Stempski, Randolph. 2002. “Direct-to-Consumer Advertising and the Demand for Cholesterol-Reducing Drugs.” Journal of Law and Economics 14(2):673–690.CrossRefGoogle Scholar
Carlton, Dennis W., and Jeffrey, M. Perloff. 1994. Modern Industrial Organization. 2nd ed. New York: HarperCollins College Division.Google Scholar
Caro, J., Klittich, W., McGuire, A., and Ford, I.. 1997. “The West of Scotland Coronary Prevention Study: Economic Benefit Analysis of Primary Prevention with Pravastatin.” British Medical Journal 315: 1577–1582.CrossRefGoogle ScholarPubMed
Caves, R.E., Whinston, M.D., and Hurwitz, M.. 1991. “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry.” Brookings Papers on Economic Activity Microeconomics (1991):1–66.CrossRefGoogle Scholar
Center for Global Development Advanced Market Commitment Working Group. 2005. “Making Markets for Vaccines: Ideas to Action.” Available at www.cgdev.org/Publications/vaccine/_files/MakingMarkets-complete.pdf. Last accessed April 28, 2005.
Claxton, K., Ginnelly, L., Sculpher, M., Philips, Z., and Palmer, S.. 2004. “A Pilot Study on the Use of Decision Theory and Value of Information Analysis as Past of the National Health Service Technology Assessment Programme. Health Technology Assessment 8(31) (whole issue).CrossRefGoogle Scholar
Clissold, D.B. 1995. “Prescription for The Orphan Drug-Act: The Impact of the FDA's 1992 Regulations and the Latest Congressional Proposals for Reform.” Food and Drug Law Journal 50(1):125–147.Google ScholarPubMed
Cochrane, A.L., Leger, A.S.St., and Moore, F.. 1978. “Health Service ‘Input’ and Mortality ‘Output’ in Developed Countries.” Journal of Epidemiology and Community Health 32(3):200–205.CrossRefGoogle ScholarPubMed
Cockburn, Iain M. 2004. “The Changing Structure of the Pharmaceutical Industry.” Health Affairs 23: 10–22.CrossRefGoogle ScholarPubMed
Cockburn, Iain, and Henderson, Rebecca. 1994. “Racing to Invest? The Economics of Competition in Ethical Drug Discovery.” Journal of Economics and Management Strategy 33: 481–519.CrossRefGoogle Scholar
Cockburn, Iain, and Henderson, Rebecca. 1996. Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery. Rand Journal of Economics 27: 32–60.Google Scholar
Cockburn, Iain M., and Henderson, Rebecca M.. 1998. “Absorptive Capacity, Co-Authoring Behavior, and the Organization of Research in Drug Discovery.” Journal of Industrial Economics 46: 157–182.CrossRefGoogle Scholar
Cockburn, Iain, and Rebecca Henderson. 1999. “The Economics of Drug Discovery,” in Ralph Landau et al., eds., Pharmaceutical Innovation, 308–330. Philadelphia: Chemical Heritage Press.
Cockburn, Iain, and Henderson, Rebecca. 2001. “Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research.” Journal of Health Economics 20(6):1033–1057.CrossRefGoogle ScholarPubMed
Cockburn, Iain M., Rebecca Henderson, and Scott Stern. 1999. “The Diffusion of Science Driven Drug Discovery, Organizational Change in Pharmaceutical Research.” National Bureau of Economic Research Working Paper 7359.
Cohen, J. 2002. “US Vaccine Supply Falls Seriously Short.” Science 295(5562):1998–2001.CrossRefGoogle Scholar
Cohen, J. 2004. “Vaccine Policy: Immunizing Kids against Flu May Prevent Deaths among the Elderly.” Science 306(5699):1123.CrossRefGoogle ScholarPubMed
Cohen, W.M., and Merrill, S.A.. 2003. Patents in the Knowledge-Based Economy: Committee on Intellectual Property Rights in the Knowledge-Based Economy. Washington, DC: National Academies Press, National Research Council (U.S.).Google Scholar
Cohen, Wesley M., Richard R. Nelson, and John P. Walsh. 2002. “Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not).” National Bureau of Economic Research Working Paper 7552.
Comanor, William S. 1964. “Research and Competitive Product Differentiation in the Pharmaceutical Industry in the United States.” Economica 31: 372–384.CrossRefGoogle Scholar
Comanor, William S. 1965. “Research and Technical Change in the Pharmaceutical Industry.” Review of Economics and Statistics 47(2):182–190.CrossRefGoogle Scholar
Conroy, Robert, Robert Harris, and Thomas Massaro. 1992. “Assessment of Risk and Capital Costs in the Pharmaceutical Industry.” Unpublished paper, University of Virginia, Darden School, June 30.
Corrigan, J. M., Greiner, A., and Erickson, S. M., eds. 2002. Fostering Rapid Advances in Health Care: Learning from System Demonstrations. Washington, DC: National Academies Press.Google Scholar
Covert, N. 2000. “Cutting Edge: A History of Fort Detrick.” Frederick, MD: Self-published. Available at www.detrick.army.mil/detrick/cutting_edge/index.cfm?chapter 12.
Crawford, Gregory S., and Shum, Matthew. 2005. “Uncertainty and Learning in Pharmaceutical Demand.” Econometrica 73(4):4.CrossRefGoogle Scholar
Cremieux, Pierre-Yves, Meilleur, Marie-Claude, Ouellette, Pierre, Petit, Patrick, Zelder, Martin, and Potvin, Ken. 2005. “Public and Private Pharmaceutical Spending as Determinants of Health Outcomes in Canada.” Health Economics 14: 107–116.CrossRefGoogle Scholar
Cremieux, Pierre-Yves, Pierre Ouellette, Marie-Clause Meilleur, Stephanie Leong, Paul Greenberg, and Howard Birnbaum. 2001. “Pharmaceutical Spending and Health Outcomes in the United States,” in Investing in Health: The Social and Economic Benefits of Health Care Innovation,” ed. by Farquhar, Irina, Summers, Kent, and Sorkin, Alan, 59–76. Oxford: Elsevier Science.Google Scholar
Cremieux, Pierre-Yves, Ouellette, Pierre, and Pilon, Caroline. 1999. “Health Care Spending as Determinants of Health Outcomes.” Health Economics 8: 627–639.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Currie, J., and Madrian, Brigitte C.. 1999. “Health, Health Insurance and the Labor Market,” in Handbook of Labor Economics, ed. by Orley Ashenfelter and David Card, 3309–3415. Amsterdam: Elsevier Science.Google Scholar
Cutler, David M. 2004. Your Money or Your Life: Strong Medicine for America's Health Care System. New York: Oxford University Press.Google Scholar
Cutler, David M., Deaton, Angus S., and Lleras-Muney, Adriana. 2006. “The Determinants of Mortality.” Journal of Economic Perspective 20(3):97–120.CrossRefGoogle Scholar
Cutler, David M., and Kadiyala, Srikanth. 2003. “The Return to Biomedical Research: Treatment and Behavioral Effects,” in Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 110–162. Chicago: University of Chicago Press.Google Scholar
Cutler, David M., and McClellan, Mark. 2001a. “Is Technological Change in Medicine Worth It?” Health Affairs 20(5):11–29.Google Scholar
Cutler, D.M., and McClellan, M.. 2001b. “Productivity Change in Health Care.” American Economic Review 91(2):281–286.CrossRefGoogle Scholar
Cutler, David, Mark McClellan, and Joseph Newhouse. 1997. “The Costs and Benefits of Intensive Treatment for Cardiovascular Disease.” Paper presented at AEI-Brookings Conference on Measuring the Prices of Medical Treatments, December 12.
Cutler, David, and Richardson, Elizabeth. 1997. “Measuring the Health of the U.S. Population.” Brookings Papers on Economic Activity: Microeconomics (1997):217–271.CrossRefGoogle Scholar
Cutler, David M., and Zeckhauser, R.. 2000. “The Anatomy of Health Insurance,” in Handbook of Health Economics, ed. by Antony J. Culyer and Joseph P. Newhouse, 563–643. Amsterdam: Elsevier.Google Scholar
Danzon, Patricia M. 2000. “Pharmaceutical Benefit Management: An Alternative Approach.” Health Affairs 19(1):24–25.CrossRefGoogle Scholar
Danzon, Patricia M. 2001. “Reference Pricing: Theory and Evidence,” in Reference Pricing and Pharmaceutical Policy, ed. by López-Casasnova, G. and Jönsson, B., 86–126.Google Scholar
Danzon, P. 2002. Pharmaceutical Price Regulation: National Policies versus Global Interests. Washington, DC: AEI Press.Google Scholar
Danzon, Patricia M., and Chao, Li-Wei. 2000. “Does Regulation Drive Out Competition in Pharmaceutical Markets?” Journal of Law and Economics 42(2):311–357.CrossRefGoogle Scholar
Danzon, Patricia M., and Furukawa, Michael. 2003. “Prices and Availability of Pharmaceuticals: Evidence from Nine Countries.” Health Affairs – Web Exclusive W3: 521–536.Google Scholar
Danzon, Patricia M., Nicholson, Sean, and Pereira, Nuno Sousa. 2005. “Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances.” Journal of Health Economics 24: 317–339.CrossRefGoogle ScholarPubMed
Danzon, P. M., Pereira, N.S., and Tejwani, S.S.. 2005. “Vaccine Supply: A Cross-National Perspective.” Health Affairs 24(3):706–717.CrossRefGoogle ScholarPubMed
Danzon, Patricia M., Wang, Y. Richard, and Wang, Liang. 2005. “The Impact of Price Regulation on the Launch Delay of New Drugs: Evidence from 25 Markets in the 1990s.” Health Economics 14: 269–292.CrossRefGoogle ScholarPubMed
Davidson, G., L.A. Blewett, K.T. Call, and SHADA Center. 2004. “Public Program Crowd-out of Private Coverage: What Are the Issues?” Research Synthesis Report No. 5. Available at www.rwjf.org/publications/synthesis/reports_and_briefs/issue5.html.
Davis, M.M., Ndiaye, S.M., Freed, G.L., Kim, C.S., and Clark, S.J.. 2003. “Influence of Insurance Status and Vaccine Cost on Physicians' Administration of Pneumococcal Conjugate Vaccine.” Pediatrics 112(3):521–526.CrossRefGoogle ScholarPubMed
Davis, M.M., Zimmerman, J.L., Wheeler, J.R.C., and Freed, G.L.. 2002. “Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations.” American Journal of Public Health 92(12):1982–1987.CrossRefGoogle ScholarPubMed
DeLaat, E.A.A. 1997. “Patents or Prizes: Monopolistic R&D and Asymmetric Information.” International Journal of Industrial Organization 15(3):369–390.CrossRefGoogle Scholar
Depression Guideline Panel, . 1993. Depression in Primary Care: Treatment of Major Depression. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.Google Scholar
Dickson, Michael, and Gagnon, Jean Paul. 2004. “Key Factors in the Rising Cost of New Drug Discovery and Development.” Nature Reviews 3: 417–428.Google ScholarPubMed
DiMasi, J.A., Hansen, R.W., and Grabowski, H.G.. 2003. “The Price of Innovation: New Estimates of Drug Development Costs.” Journal of Health Economics 22(2):151–185.CrossRefGoogle Scholar
DiMasi, J.A., Hansen, R.W., Grabowski, H.G., and Lasagna, L.. 1991. “Cost of Innovation in the Pharmaceutical Industry.” Journal of Health Economics 10(2):107–142.CrossRefGoogle ScholarPubMed
Dion, M.R., and Pavetti, L.. 2000. Access to and Participation in Medicaid and the Food Stamp Program: A Review of the Recent Literature. Washington, DC: Mathematica Policy Research.Google Scholar
Donaldson, C., Currie, G., and Mitton, C.. 2002. “Cost-Effectiveness Analysis in Health Care: Contraindications.” British Medical Journal 325: 891–894.CrossRefGoogle ScholarPubMed
Donohue, Julie M. 2003. “The Evolving Roles of Consumers and Consumer Protection: The History of Prescription Drug Advertising.” Milbank Quarterly 84(4):659–694.CrossRefGoogle Scholar
Donohue, Julie M., and Berndt, Ernst R.. 2004. “Effect of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants.” Journal of Public Policy & Marketing 23(2):115–127.CrossRefGoogle Scholar
Donohue, Julie M., Berndt, Ernst R., Rosenthal, Meredith, Epstein, Arnold M., and Frank, Richard G.. 2004. “Effects of Pharmaceutical Promotion on Adherence to Guideline Treatment of Depression.” Medical Care 42(2):1176–1185.CrossRefGoogle Scholar
Dorfman, Robert, and Steiner, Peter O.. 1954. “Optimal Advertising and Optimal Quality.” American Economic Review 44(5):826–836.Google Scholar
Dornbusch, Rudiger, and Fischer, Stanley. 1994. Macroeconomics. 6th ed. New York: McGraw-Hill.Google Scholar
Downs, Anthony. 1957. An Economic Theory of Democracy. New York: HarperCollins College Division.Google Scholar
Drummond, M.F., and Pang, F.. 2001. “Transferability of Economic Evaluation Results.” in Economic Evaluation in Health Care: Merging Theory with Practice, ed. by M.F. Drummond and A. McGuire, 256–327. Oxford: Oxford University Press.Google Scholar
Drummond, M.F., and Sculpher, M.J.. 2005. “Common Methodological Flaws in Economic Evaluations.” Medical Care 43(4):5–14.CrossRefGoogle ScholarPubMed
Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., and Stoddart, G.L.. 2005. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press.Google Scholar
D'Souza, Juliet, and Megginson, William L.. 1999. “The Financial and Operating Performance of Privatized Firms during the 1990s.” Journal of Finance 54(4):1397–1438.CrossRefGoogle Scholar
Dubois, Robert W. 2003. “Pharmaceutical Promotion: Don't Throw the Baby Out with the Bathwater.” Health Affairs – Web Exclusive W3: 96–103.Google Scholar
Dubois, Robert W., Chawla, Anita J., Neslusan, Cheryl A., et al. 2000. “Explaining Drug Spending Trends: Does Perception Match Reality?” Health Affairs 19: 231–239.CrossRefGoogle ScholarPubMed
Duggan, Mark. 2005. “Do New Prescription Drugs Pay for Themselves? The Case of Second-Generation Antipsychotics.” Journal of Health Economics 24: 1–31.CrossRefGoogle ScholarPubMed
Ehrlich, Isaac, Gallais-Hamonno, Georges, Liu, Zhiqiang, and Lutter, Randall. 1994. “Productivity Growth and Firm Ownership: An Analytical and Empirical Investigation.” Journal of Political Economy 102(5):1006–1038.CrossRefGoogle Scholar
Ellison, G.S., and F. Ellison. 2000. “Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration.” Working paper, MIT, Cambridge, MA.
Ellison, Sara Fisher, and Wallace P. Mullin. 1997. “Gradual Incorporation of Information into Stock Prices: Empirical Strategies.” National Bureau of Economic Research Working Paper 6218.
Emmons, Willis A., and Ashok Nimgade. 1991. “Burroughs Wellcome and AZT.” Harvard Business School Case No. 9-792-004, Cambridge, MA.
Enserink, M. 2004. “Influenza: Crisis Underscores Fragility of Vaccine Production System.” Science 306(5695):385.CrossRefGoogle ScholarPubMed
EPIC Investigators, . 1994. “Use of Monoclonal Antibody Directed against the Platelet Glycoprotein lib/111a Receptor in High-Risk Coronary Angioplasty.” New England Journal of Medicine 330: 956–961.Google Scholar
Fama, E.F. 1980. “Agency Problems and the Theory of the Firm.” Journal of Political Economy 88(2):288–307.CrossRefGoogle Scholar
Fama, E.F., Fisher, L., Jensen, M., and Roll, R.. 1969. “The Adjustment of Stock Prices to New Information.” International Economic Review 10(1):1–21.CrossRefGoogle Scholar
Farber, Henry S., and Brazerman, Max H.. 1986. “The General Basis of Arbitrator Behavior: An Empirical Analysis of Conventional and Final-Offer Arbitration.” Econometrica 54: 819–844.CrossRefGoogle Scholar
Farlow, A. 2004. “Analysis of the Problems of R&D Finance for Vaccines and an Appraisal of Advance Purchase Commitments.” Preprint. Oxford: University of Oxford. Available at www.economics.ox.ac.uk/members/andrew.farlow/VaccineRD.pdf#search='farlow%20and%20analysis%20of%20the%20problems.
Farlow, Andrew, Donald W. Light, Richard T. Mahoney, and Roy Widdus. 2005. “Concerns Regarding the ‘Making Markets for Vaccines’ Submission to the Commission on Intellectual Property Rights, Innovation and Public Health.” Available at www.who.int/intellectualproperty/en/. Last accessed May 10, 2005.
Farquhar, Irina, Summers, Kent, and Sorkin, Alan, eds. 2001. Benefits of Health Care Innovation. Oxford: Elsevier Science.Google Scholar
Federal Trade Commission, . 2002. Generic Competition Prior to Patent Expiration: An FTC Study. Washington, DC: Federal Trade Commission.Google Scholar
FinFacts. Global/World Income per Capita/Head 2005. 2005. Available at www.finfacts.com/biz10/globalworldincomepercapita.htm. Last accessed October 20, 2005.
Finkel, M., and Buron, L.. 2001. Study on Section 8 Voucher Success Rates. Cambridge, MA: Diane Publishing.Google Scholar
Finkelstein, A. 2004. “Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry.” Quarterly Journal of Economics 119(2):527–564.CrossRefGoogle Scholar
Forbes, Steve. 2005. “Rich Freeloader Countries – France, German, Canada – Rob America on Health Care.” USA Next. Available at www.usanext.org/full_story.cfm?areticle_id=16&category_id=3. Last accessed October 30, 2005.
Fortune Magazine. 2005. The 2005 Fortune 500: Most Profitable Industries: Return on Revenues. Available at www.fortune.com/fortune/subs/fortune500/topperformers/industrysnapshot/0,23619,prof_pct_rev,00.html.
Frank, John W., and J. Fraser Mustard. 1998. “The Determinants of Health from a Historical Perspective.” The Founders' Network. Available at www.founders.net/fn/papers.nsf.
Frank, R.G., Dewa, C., Holt, E., et al. 1995. “The Demand for Childhood Immunizations: Results from the Baltimore Immunization Study.” Inquiry 32(2):164–173.Google ScholarPubMed
Frank, R.G., and Salkever, D.S.. 1992. “Pricing, Patent Loss and the Market for Pharmaceuticals.” Southern Economic Journal 59: 165–179.CrossRefGoogle Scholar
Frank, R.G., and Salkever, D.S.. 1997. “Generic Entry and Pricing of Pharmaceuticals.” Journal of Economics and Management Strategy 6(1):75–90.CrossRefGoogle Scholar
Frech, H.E. III, and Miller, Richard D., Jr. 1999. The Productivity of Health Care and Pharmaceuticals: An International Comparison. Washington, DC: AEI Press.Google Scholar
Freed, G.L., Clark, S.J., Pathman, D.E., Schectman, R., and Serling, J.. 1999. “Impact of North Carolina's Universal Vaccine Purchase Program by Children's Insurance Status.” Archives of Pediatric and Adolescent Medicine 153(7):748–754.CrossRefGoogle ScholarPubMed
Freed, G., and A. Cowan. 2002. “State-Level Perspectives on Vaccine Purchase Financing.” Unpublished. Available from the Institute of Medicine, Washington, DC.
Freed, G.L., Davis, M.M., Andreae, M.C., Bass, S., and Weinblatt, H.. 2002. “Reimbursement for Prevnar: A Modern-Day Version of Hercules and the Hydra.” Pediatrics 110(2):399–400.CrossRefGoogle ScholarPubMed
Fuchs, Victor R., and Zeckhauser, Richard. 1987. “Valuing Health: A ‘Priceless’ Commodity.” American Economic Review 77(2):263–268.Google ScholarPubMed
Gafni, A., and Birch, S.. 1993. “Guidelines for the Adoption of New Technologies: A Prescription for Uncontrolled Growth in Expenditures and How to Avoid the Problem.” Canadian Medical Association Journal 148(6):913–917.Google ScholarPubMed
Gahart, Martin T., Duhamel, Louise M., Dievler, Anne, and Price, Roseanne. 2003. “Examining the FRDA's Oversight of Direct-to-Consumer Advertising.” Health Affairs – Web Exclusive W3: 120–123.Google Scholar
Gallini, N., and Scotchmer, S.. 2002. “Intellectual Property: When Is It the Best Incentive Mechanism?” in Innovation Policy and the Economy, ed. by A. Jaffe, J. Lerner, and S. Stern, 2:51–78. Cambridge, MA: MIT Press.Google Scholar
Gambardella, Alfonso. 1995. Science and Innovation: The U.S. Pharmaceutical Industry during the 1980s. Cambridge: Cambridge University Press.CrossRefGoogle Scholar
George, B., Harris, A., and Mitchell, A.. 2001. “Cost-Effectiveness Analysis and the Consistency of Decision-Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996).” PharmacoEconomics 19(11):1103–1109.CrossRefGoogle Scholar
Georges, P., Ann, A. Margaret, Jeffrey, P.D., Michael, D.D., et al. 2003. “Strengthening the Supply of Routinely Recommended Vaccines in the United States: Recommendations from the National Vaccine Advisory Committee.” Journal of the American Medical Association 290(23):3122–3128.Google Scholar
Giaccotto, Carmelo, Santerre, Rexford E., and Vernon, John A.. 2005. “Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry.” Journal of Law and Economics 48(1):195–214.CrossRefGoogle Scholar
Giffin, R., Stratton, K., and Chalk, R.. 2004. “Childhood Vaccine Finance and Safety Issues.” Health Affairs 23(5):98–111.CrossRefGoogle ScholarPubMed
Glassman, James K. 2005. “Free Riding Isn't Free.” Available at www.techcentralstation.com/022304F.html. Last accessed October 28, 2005.
Glied, Sherry. 2003. “Health Care Costs: On the Rise Again.” Journal of Economic Perspective 17(2):125–148.CrossRefGoogle Scholar
Global Alliance for TB Drug Development, . 2001. Economics of TB Drug Development. New York: Global Alliance for TB Drug Development. Available at http://66.216.124.114/pdf/Economics%20Report%20Full%20(final).pdf.Google Scholar
Global Health Policy Research Network. 2004. “Making Markets for Vaccines.” Pull Mechanisms Working Group. Available at www.cgdev.org/globalhealth/proj_pull.cfm.
Gold, M., Siegel, J.E., Russell, L.B., and Weinstein, M.C., eds. 1996. Cost Effectiveness in Health and Medicine. Oxford: Oxford University Press.Google Scholar
Goodman, J.C., and Musgrave, G.L.. 1987. Freedom of Choice in Health Insurance. Dallas: National Center for Policy Analysis.Google Scholar
Goolsbee, Austan. 1988. “Does Government R&D Policy Mainly Benefit Scientists and Engineers?” American Economic Review 88(2):298–302.Google Scholar
Grabowski, Henry. 2004. “Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures.” PharmacoEconomics 22(Suppl. 2):15–24.CrossRefGoogle ScholarPubMed
Grabowski, Henry. 2005. “Encouraging the Development of New Vaccines.” Health Affairs 24(3):697–700.CrossRefGoogle ScholarPubMed
Grabowski, Henry, Cockburn, Iain, and Long, Genia. 2006. “The Market for Follow-On Biologics: How Will It Evolve.” Health Affairs 25(5):1291–1301.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Kyle, Margaret. 2006. “Generic Competition and Market Exclusivity Periods in Pharmaceuticals.” Managerial and Decision Economics, forthcoming.Google Scholar
Grabowski, Henry, and Mullins, C. Daniel. 1997. “Pharmacy Benefit Management Cost-Effectiveness Analysis and Drug Formulary Decisions.” Social Science and Medicine 45(4):535–544.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Vernon, John. 1986. “Longer Patents for Lower Imitation Barriers: The 1984 Drug Act.” American Economic Review: Papers and Proceedings 76(2):195–198.Google Scholar
Grabowski, Henry, and Vernon, John M.. 1990. “A New Look at the Return and Risks to Pharmaceutical R&D.” Management Science 36: 804–821.CrossRefGoogle Scholar
Grabowski, Henry, and Vernon, John. 1992. “Brand Loyalty Entry and Price Competition in Pharmaceuticals after the 1984 Act.” Journal of Law and Economics 35(2):331–350.CrossRefGoogle Scholar
Grabowski, Henry, and Vernon, John M.. 1994. “Returns on New Drug Introductions in the 1980s.” Journal of Health Economics 13: 383–406.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Vernon, John. 1996. “Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade.” PharmacoEconomics 10 (Suppl. 2):110–123.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Vernon, John. 2000. “Effective Patent Life in Pharmaceuticals.” International Journal of Technology Management 19(1–2):98–120.CrossRefGoogle Scholar
Grabowski, Henry, Vernon, John M., and Thomas, Lacy Glenn. 1978. “Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry.” Journal of Law and Economics 21(1):133–163.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Wang, Richard. 2006. “The Quantity and Quality of Worldwide New Drug Introductions: 1982–2003.” Health Affairs 25(2):452–460.CrossRefGoogle ScholarPubMed
Greene, Jeremy A. 2004. “Attention to ‘Details’: Etiquette and the Pharmaceutical Salesman in Postwar America.” Social Studies in Science 34(2):271–292.CrossRefGoogle Scholar
Gruber, J. 1994. “The Incidence of Mandated Maternity Benefits.” American Economic Review 84(3):622–642.Google ScholarPubMed
Gruber, J., ed. 2000. “Health Insurance and the Labor Market,” in Handbook of Health Economics, ed. by Antony J. Culyer and Joseph P. Newhouse, 645–706. Amsterdam: Elsevier Science.Google Scholar
Guedj, Ilan, and David Scharfstein. 2004. “Organizational Scope and Investment: Evidence from the Drug Development Strategies of Biopharmaceutical Firms.” National Bureau of Economic Research Working Paper.
Gupta, Nandini. 2002. “Partial Privatization and Firm Performance.” Unpublished working paper, Columbia University. August. Available at www-1.gsb.columbia.edu/divisions/management/seminar/papers/gupta.pdf.
Hall, Bronwyn, H. 1993, “R&D Tax Policy during the Eighties: Success or Failure?” in Tax Policy and the Economy 7, ed. by James Poterba, 1–35. Cambridge, MA: MIT Press.Google Scholar
Hall, Bronwyn H., and Reenen, John. 2000. “How Effective Are Fiscal Incentives for R&D? A New Review of the Evidence.” Research Policy 29: 449–469.CrossRefGoogle Scholar
Hall, Robert E., and Jones, Charles I.. 1999. “Why Do Some Countries Produce So Much More Output per Worker than Others?” Quarterly Journal of Economics 114(1):83–116.CrossRefGoogle Scholar
Hansen, Ronald W. 1979. “The Pharmaceutical Development Process: Estimates of Development Costs and Times and the Effects of Proposed Regulatory Changes,” in Issues in Pharmaceutical Economics, ed. Robert I. Chien, 151–187. Boston: Lexington Books.Google Scholar
Hart, Oliver D., Shleifer, Andrei, and Vishny, Robert W.. 1997. “The Proper Scope of Government: Theory and an Application to Prisons.” Quarterly Journal of Economics 112(4):1126–1161.CrossRefGoogle Scholar
Hassett, Kevin, and R. Glenn Hubbard. 1996. “Tax Policy and Investment.” Unpublished paper, Federal Reserve Board of Governors and Columbia University Business School.
Heffler, Stephen, Smith, Sheila, Keehan, Sean, Borger, Christine, Clemens, M. Kent, and Truffer, Christopher. 2005. “U.S. Health Spending for 2004–2014.” Health Affairs – Web Exclusive W5: 74–85.Google Scholar
Henderson, Rebecca, and Cockburn, Iain. 1996. “Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery.” RAND Journal of Economics 27(1):32–59.CrossRefGoogle ScholarPubMed
Hill, S.R., Mitchell, A.S., and Henry, D.A.. 2000. “Problems with the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme.” Journal of the American Medical Association 283: 2116–2121.CrossRefGoogle ScholarPubMed
Hinman, A. 2004. “Institute of Medicine Report on Financing Vaccines in the 21st Century: National Vaccine Advisory Committee/National Vaccine Program Office Response.” Available at www.hhs.gov/nvpo/nvac/NVAC-IOM100604.htm.
Hinman, A. 2005. “Addressing the Vaccine Financing Conundrum.” Health Affairs 24(3):701–704.CrossRefGoogle ScholarPubMed
Hoek, Janet, Gendall, Philip, and Calfee, John. 2004. “Direct-to-Consumer Advertising of Prescription Medicines in the United States and New Zealand: An Analysis of Regulatory Approaches and Consumer Responses.” International Journal of Advertising 23: 197–227.CrossRefGoogle Scholar
Hollis, A. 2005a. “An Efficient Reward System for Pharmaceutical Innovation.” Preprint. Available at http://econ.ucalgary.ca/fac-files/ah/drugprizes.pdf#search='hollis%20and%20an%20efficient%20reward%20system.
Hollis, A. 2005b. “An Optional Reward System for Neglected Disease Drugs.” Mimeo, University of Calgary.
Hollon, Matthew F. 1999. “Direct-to-Consumer Prescription Drugs: Creating Consumer Demand.” Journal of the American Medical Association 281(4):382–384.CrossRefGoogle ScholarPubMed
Holmstrom, Bengt, and Tirole, Jean. 1993. “Market Liquidity and Performance Monitoring.” Journal of Political Economy 101: 678–709.CrossRefGoogle Scholar
Hotz, J., Ahituv, A., and Philipson, T.. 1996. “The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS.” Journal of Human Resources 21(4):869–897.Google Scholar
Hsieh, Chee-Ruey, and Frank A. Sloan. 2006. “Adoption of Pharmaceutical Innovation and the Growth of Drug Expenditure: The Taiwanese Experience.” Working Paper, Duke University.
Hsu, J.C., and E.S. Schwartz. 2003. “A Model of R&D Valuation and the Design of Research Incentives.” National Bureau of Economic Research Working Paper 10041.
Hubbard, R.G., Skinner, J., and Zeldes, S.P.. 1995. “Precautionary Saving and Social Insurance.” Journal of Political Economy 103: 360–399.CrossRefGoogle Scholar
Hudson, John. 2000. “Generic Take-Up in the Pharmaceutical Market Following Patent Expiry: A Multi-Country Study.” International Review of Law and Economics 20: 205–221.CrossRefGoogle Scholar
Hume, C., and Schmitt, W.. 2001. “Pharma's Prescription.” Chemical Week, April 11, 21.Google Scholar
Hurwitz, Mark A., and Caves, Richard E.. 1988. “Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals.” Journal of Law and Economics 31, no. 5: 299–320.CrossRefGoogle Scholar
Huskamp, H.A., Rosenthal, M.B., Frank, R.G., and Newhouse, J.P.. 2000. “The Medicare Prescription Drug Benefit: How Will the Game Be Played?” Health Affairs 19(2):8–23.CrossRefGoogle ScholarPubMed
Iglehart, John K., ed. 2004. “Variations Revisited: A Supplement to Health Affairs.” Health Affairs – Web Exclusive 23: 3–4.Google Scholar
Iizuka, Toshi. 2004. “What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs?” Journal of Industrial Economics 52(3):349–379.CrossRefGoogle Scholar
Iizuka, Toshi, and Ginger Z. Jin. 2003. “The Effects of Direct-to-Consumer Advertising in the Prescription Drug Markets.” Unpublished working paper, Vanderbilt University, Owen Graduate School of Management, September 29.
Iizuka, Toshi, and Jin, Ginger Z.. 2005a. “The Effect of Prescription Drug Advertising on Doctor Visits.” Journal of Economics and Management Strategy, forthcoming.CrossRefGoogle Scholar
Iizuka, Toshi, and Ginger Z. Jin. 2005b. “Direct to Consumer Advertising and Prescription Choice.” Working paper, Vanderbilt University, Owen Graduate School of Management.
IMS, . 2004. Global Pharmaceutical Review. October. London.Google Scholar
IMS Intelligence. 2005. Chart 1. PowerPoint Presentation Supplied via e-mail by Raymond Hill of IMS, May 21.
Institute of Medicine, . 2000. Calling the Shots: Immunization Finance Policies and Practices. Washington, DC: National Academies Press.Google Scholar
Institute of Medicine, . 2003. Hidden Costs, Value Lost: Uninsurance in America. Washington, DC: National Academies Press, 2003.Google Scholar
Institute of Medicine, . 2004. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press.Google Scholar
Institute of Medicine, , Corrigan, J., Greiner, A., and Erickson, S.M.. 2002. Fostering Rapid Advances in Health Care: Learning from System Demonstrations. Washington, DC: National Academies Press.Google Scholar
Ives, D., Lave, J., Traven, N., and Kuller, L.. 1994. “Impact of Medicare Reimbursement on Influenza Vaccination Rates in the Elderly.” Preventive Medicine 23: 134–141.CrossRefGoogle ScholarPubMed
Jensen, Elizabeth J. 1987. “Research Expenditures and the Discovery of New Drugs.” Journal of Industrial Economics 36: 83–95.CrossRefGoogle Scholar
Jensen, G.A., and Morrisey, M.A.. 1999. “Employer-Sponsored Health Insurance and Mandated Benefit Laws.” Milbank Quarterly 77(4):425–459.CrossRefGoogle ScholarPubMed
Jewkes, John, Sawyers, David, and Stillerman, Richard. 1958. The Sources of Invention. London: Macmillan.Google Scholar
Jones, Charles. 1998. Introduction to Economic Growth. New York: W.W. Norton.Google Scholar
Joskow, P.L. 1989. “Regulatory Failure, Regulatory Reform, and Structural-Change in the Electrical-Power Industry.” Brookings Papers on Economic Activity (1998):125–208.CrossRefGoogle Scholar
Juhl, R.P. 2000. “Prescription to Over-the-Counter Switch: A Regulatory Perspective.” Clinical Therapeutics 20(Supp. C):111–117.CrossRefGoogle Scholar
Kahn, A. 1971. The Economics of Regulation: Principles and Institutions. New York: Wiley.Google Scholar
Kaiser Family Foundation. 2001. Prescription Drug Trends: A Chartbook UpdateWashington, DC.
Kaiser Family Foundation. 2002. Employer Health Benefits: 2002 Annual Survey. Washington, DC.
Kaiser Family Foundation. 2005. Prescription Drug Coverage for Medicare Beneficiaries: A Summary of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Available at www.kff.org/medicare/6112.cfm. Last accessed November 5, 2005.
Kanavos, Panos, and Reinhardt, Uwe E.. 2003. “Reference Pricing For Drugs: Is It Compatible with U.S. Health Care?” Health Affairs 22(3):16–30.CrossRefGoogle ScholarPubMed
Kettler, Hannah E. 1999. “Updating the Cost of a New Chemical Entity.” London: Office of Health Economics.
Keynes, John Maynard. 1936. The General Theory of Employment, Interest, and Money. London: Macmillan.Google Scholar
Kim, Jong-Il, and Lau, Lawrence J.. 1994. “The Sources of Economic Growth of the East Asian Newly Industrialized Countries.” Journal of the Japanese and International Economies 8: 235–271.CrossRefGoogle Scholar
Kitch, E.W. 1977. “The Nature and Function of the Patent System.” Journal of Law and Economics 10: 265–290.CrossRefGoogle Scholar
Klein, Daniel B. 2005. “Policy Medicine versus Policy Quackery: Economists against the FDA.” Knowledge, Technology, and Policy 31(1):92–101.Google Scholar
Klick, J., and Sara Markowitz. 2003. “Are Mental Health Insurance Mandates Effective? Evidence from Suicides.” National Bureau of Economic Research Working Paper 9994.
Kobelt, G., Jönsson, L., Young, A., and Eberhardt, K.. 2003. “The Cost-Effectiveness of Infliximab (Remicade) in the Treatment of Rheumatoid Arthritis in Sweden and the United Kingdom Based on the ATTRACT Study.” Rheumatology 42: 326–335.CrossRefGoogle ScholarPubMed
Kravitz, Richard I., Epstein, Ronald M., Feldman, Mitchell D., Franz, Carol E., Azari, Rahman, Wilkes, Michael S., Hinton, Ladson, and Franks, Peter. 2005. “Influence of Patients' Requests for Direct-to-Consumer Advertised Antidepressants: A Randomized Controlled Trial.” Journal of the American Medical Association 293(16):1995–2002.CrossRefGoogle ScholarPubMed
Kreling, D.H., T. Collins, H. Lipton, and K.C. Hertz. 1996. “Assessing the Impact of Pharmacy Benefit Managers.” HCFA Contract Report, HCFA 95-023/PW, September 30.
Kremer, M. 1998. “Patent Buyouts: A Mechanism for Encouraging Innovation.” Quarterly Journal of Economics 113(4):1137–1167.CrossRefGoogle Scholar
Kremer, M. 2000a. “Creating Markets for New Vaccines Part I: Rationale.” National Bureau of Economic Research Working Paper 7716.
Kremer, M. 2000b. “Creating Markets for New Vaccines Part II: Design Issues.” National Bureau of Economic Research Working Paper 7717.
Kremer, M., and Glennerster, R.. 2004. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton, NJ: Princeton University Press.Google Scholar
Kremer, M., and C.M. Snyder. 2003. “Why Are Drugs More Profitable than Vaccines?” National Bureau of Economic Research Working Paper 9833.
Kronick, R., and Gilmer, T.. 2002. “Insuring Low-Income Adults: Does Public Coverage Crowd Out Private?” Health Affairs 21(1):225–239.CrossRefGoogle ScholarPubMed
Laffont, J.-J., and Tirole, J.. 1993. A Theory of Incentives in Procurement and Regulation. Cambridge, MA: MIT Press.Google Scholar
Landau, Ralph, et al. 1999. Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press.Google Scholar
Lanjouw, J. 2004. “Outline of Foreign Filing License Approach.” Washington, DC: Center for Global Development & Global Health Policy Research Network. Available at www.cgdev.org/docs/FFLOutline.pdf.
Lanjouw, J.O., and M. MacLeod. 2005. “Statistical Trends in Pharmaceutical Research for Poor Countries.” Available at www.who.int/intellectualproperty/studies. Last accessed May 10, 2005.
Learner, Josh, and Merges, Robert P.. 1998. “The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry.” Journal of Industrial Economics 46: 125–156.CrossRefGoogle Scholar
Learner, Josh, and Alexander Tsai. 2000. “Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances.” National Bureau of Economic Research Working Paper W7464.
Leffler, Keith B. 1981. “Promotion or Information? The Economics of Prescription Drug Advertising.” Journal of Law and Economics 24(2):45–74.CrossRefGoogle Scholar
Levin, Richard C., Klevorick, Alvin K., Nelson, Richard R., and Winter, Sidney G.. 1987. “Appropriating the Returns from Industrial Research and Development.” Brookings Papers on Economic Activity 3: 783–820.CrossRefGoogle Scholar
Lichtenberg, Frank R. 1984. “The Relationship between Federal Contract R&D and Company R&D.” American Economic Review 74(2):73–78.Google Scholar
Lichtenberg, Frank R. 1986. “Energy Prices and Induced Innovation.” Research Policy 15: 67–75.CrossRefGoogle Scholar
Lichtenberg, Frank R. 1987. “Changing Market Opportunities and the Structure of R&D Investment: The Case of Energy.” Energy Economics 9(3):154–158.CrossRefGoogle Scholar
Lichtenberg, Frank R. 1988. “The Private R&D Investment Response to Federal Design and Technical Competitions.” American Economic Review 78(3):550–559.Google Scholar
Lichtenberg, Frank R. 1996. “The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality.” National Bureau of Economic Research Working Paper 5418.
Lichtenberg, Frank R. 2001a. “The Allocation of Publicly Funded Biomedical Research,” in Medical Care Output and Productivity, Studies in Income and Wealth vol. 62, ed. by Ernst Berndt and David Cutler, 565–589. Chicago: University of Chicago Press.Google Scholar
Lichtenberg, Frank R. 2001b. “The Effect of New Drugs on Mortality from Rare Diseases and HIV.” National Bureau of Economic Research Working Paper 8677.
Lichtenberg, Frank R. 2003a. “Pharmaceutical Innovation, Mortality Reduction, and Economic Growth.” in Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 74–109. Chicago: University of Chicago Press.Google Scholar
Lichtenberg, Frank R. 2003b. “The Effect of New Drugs on HIV Mortality in the U.S., 1987–1998.” Economics and Human Biology 1: 259–266.CrossRefGoogle Scholar
Lichtenberg, Frank R. 2003c. “The Benefits to Society of New Drugs: A Survey of the Econometric Evidence.” Proceedings of the Federal Reserve Bank of Dallas (September):43–59.Google Scholar
Lichtenberg, Frank R. 2004a. “Public Policy and Innovation in the U.S. Pharmaceutical Industry,” in Public Policy and the Economics of Entrepreneurship, ed. by Douglas Holtz-Eakin and Harvey S. Rosen, 83–113. Cambridge, MA: MIT Press.Google Scholar
Lichtenberg, Frank R. 2004b. “Sources of U.S. Longevity Increase, 1960–2001.” Quarterly Review of Economics and Finance 44(3):369–389.CrossRefGoogle Scholar
Lichtenberg, Frank R. 2005a. “Pharmaceutical Innovation and the Burden of Disease in Developed and Developing Countries.” Journal of Medicine and Philosophy 30(6):663–690.CrossRefGoogle Scholar
Lichtenberg, Frank R. 2005b. “The Impact of New Drug Launches on Longevity: Evidence from Longitudinal Disease-level Data from 52 Countries, 1982–2001.” International Journal of Health Care Finance and Economics 5(1):47–73.CrossRefGoogle Scholar
Lichtenberg, Frank R., and Suchin Virabhak. 2002. “Pharmaceutical Embodied Technical Progress, Longevity, and Quality of Life: Drugs as “Equipment for Your Health.” National Bureau of Economic Research Working Paper 9351.
Lichtenberg, F., and J. Waldfogel. 2003. “Does Misery Love Company? Evidence from Pharmaceutical Markets before and after the Orphan Drug Act.” National Bureau of Economic Research Working Paper 9750.
Light, Donald W., and Warburton, Rebecca N.. 2005. “Extraordinary Claims Require Extraordinary Evidence.” Journal of Health Economics 24(5):1030–1033.CrossRefGoogle ScholarPubMed
Ling, Davina C., Berndt, Ernst R., and Kyle, Margaret K.. 2002. “Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales.” Journal of Law and Economics 14: 691–723.CrossRefGoogle Scholar
Livernois, J.R. 1988. “Estimates of Marginal Discovery Costs for Oil and Gas.” Canadian Journal of Economics 21(2):379–393.CrossRefGoogle Scholar
López-Casasnovas, G., and Jönsson, B., eds. 2001. Reference Pricing and Pharmaceutical Policy. Barcelona: Springer Verlag Ibéria.Google Scholar
López-Casasnovas, G., and Puig-Junoy, J.. 2001. “Review of the Literature on Reference Pricing,” in Reference Pricing and Pharmaceutical Policy, ed. G. López-Casasnovas and B. Jönsson, 1–41. Barcelona: Springer Verlag Ibéria.Google Scholar
Lo Sasso, A.T., and Buchmueller, T.C.. 2004. “The Effect of the State Children's Health Insurance Program on Health Insurance Coverage.” Journal of Health Economics 23(5):1059–1082.CrossRefGoogle ScholarPubMed
Luman, E.T., Barker, L.E., Shaw, K.M., et al. 2005. “Timeliness of Childhood Vaccinations in the United States: Days Undervaccinated and Number of Vaccines Delayed.” Journal of the American Medical Association 293(10):1204–1211.CrossRefGoogle ScholarPubMed
Lurie, N., Manning, W.G., Peterson, C., et al. 1987. “Preventive Care: Do We Practice What We Preach?” American Journal of Public Health 77: 801–804.CrossRefGoogle ScholarPubMed
Mackenbach, J.P. 1991. “Health Care Expenditure and Mortality from Amenable Conditions in the European Community.” Health Policy 19: 245–255.CrossRefGoogle ScholarPubMed
Manca, A., Lambert, P., Hahn, S., Sculpher, M.J., and Rice, N.. 2004. “Exploring the Generalisability by Location of Multilevel Trial-Based CEA Results: The Case of Bayesian Hierarchical Linear Modeling,” in 5th European Conference of Health Economics, 542. London: Open Mind Journals.Google Scholar
Mansfield, Edwin. 1977. The Production and Application of New Industrial Technology. New York: W.W. Norton.Google Scholar
Mansfield, Edwin. 1986. “Patents and Innovation: An Empirical Study.” Management Science 32(2):173–181.CrossRefGoogle Scholar
Masson, A., and R. Steiner. 1985. “Generic Substitution and Prescription Drug Prices: Economic Effects of State Drug Product Selection Laws.” Staff Report of the Bureau of Economics, FTC, Washington, DC, October.
Maurer, S. 2005. “The Right Tool(s): Designing Cost-Effective Strategies for Neglected Disease Research.” Geneva: WHO Commission on Intellectual Property Rights, Innovation, and Public Health. Available at www.who.int/intellectualproperty/studies/research_development/en/.
Maurer, S., Rai, A., and Sali, A.. 2004. “Finding Cures For Tropical Diseases: Is Open Source an Answer?” PLOS: Medicine 1: 183–186. Available at http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0010056.Google ScholarPubMed
Maurer, S., and Scotchmer, S.. 2004. “Procuring Knowledge,” in Advances in the Study of Entrepreneurship, Innovation and Growth, ed. by G. Libecap, 15:1–31. Greenwich, CT: JAI Press.Google Scholar
McCarran, E. 1991. “Rx to OTC Switches: Promises and Pitfalls.” Medical Marketing and Media13–26.Google Scholar
McGuire, T.G. 2003. “Setting Prices for New Vaccines (in Advance).” International Journal of Health Care Finance and Economics 3(3):207–224.CrossRefGoogle Scholar
Megginson, William L., and Netter, Jeffry M.. 2001. “From State to Market: A Survey of Empirical Studies on Privatization.” Journal of Economic Literature 39(2):321–389.CrossRefGoogle Scholar
Meltzer, M.I., Cox, N.J., and Fukuda, K.. 1999. “The Economic Impact of Pandemic Influenza in the United States: Priorities for Intervention.” Emerging Infectious Disease 5(5):659–671.CrossRefGoogle ScholarPubMed
, Menzin J, Oster, G., Davies, L., Drummond, M.F., Greiner, W., Lucioni, C., Merot, J.L., Rossi, F., Schulenberg, V.D., and Souetre, E.. 1996. “A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis.” International Journal of Technology Assessment in Health Care 12(1):52–61.Google Scholar
Merrill, S.A., Levin, R.C., and Myers, M.B.. 2004. A Patent System for the 21st Century. Washington, DC: National Academies Press.Google Scholar
Millenson, Michael L. 2004. “Getting Doctors to Say Yes to Drugs: The Cost and Quality Impact of Drug Company Marketing to Physicians.” Chicago: Blue Cross Blue Shield Association. Available at www.bcbs.com/coststudies/reports/Drug_Co_Marketing_Report.pdf. Last accessed November 20, 2005.
Miller, Richard D., Jr., and Frech, H. E. III. 2004. Health Care Matters: Pharmaceuticals, Obesity, and the Quality of Life. Washington, DC: AEI Press.Google Scholar
Mitchell, V.S., Philipose, N.M., and Sanford, J.P., eds. 1993. The Children's Vaccine Initiative: Achieving the Vision. Washington, DC: National Academy Press.Google Scholar
Morgan, Steven G. 2002. “Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan.” Health Services Research 37: 1243–1266.CrossRefGoogle ScholarPubMed
Mueller, D. 1986. The Persistence of Profits. Cambridge: Cambridge University Press.Google Scholar
Murphy, Kevin, and Topel, Robert H.. 2003a. “The Economic Value of Medical Research,” in Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 41–73. Chicago: University of Chicago Press.CrossRefGoogle Scholar
Murphy, Kevin M., and Topel, Robert H.. 2003b. Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL: University of Chicago Press.CrossRefGoogle Scholar
Murphy, Kevin M., and Robert H. Topel. 2005. “The Value of Health and Longevity.” University of Chicago Working Paper.
Myers, Stewart. 1999. “Measuring Pharmaceutical Risk and the Cost of Capital,” in Risk and Return in the Pharmaceutical Industry, ed. by Jon Sussex and Nick Marchant, 59–76. London: Office of Health Economics.Google Scholar
Nace, N., Larson, C., Lester, T., and Kosinski, J.. 1999. “Perceived Barriers to Childhood Immunization: A Physician and Parent Survey in a Southeastern Urban/Rural Community.” Tennessee Medicine 92(7):265–268.Google Scholar
National Association of Boards of Pharmacy. 2004. Survey of Pharmacy Law for 2003–2004. Park Ridge, IL: NABC.
National Institute for Clinical Excellence (NICE). 2000. “Guidance on the Use of Zanamivir (Relenza) in the Treatment of Influenza.” Technology Appraisal Guidance No. 15. London: NICE.
National Institute for Clinical Excellence (NICE). 2004. Guide to the Methods of Technology Appraisal. London: NICE.
National Science Council (Taiwan). 2004. Indicators of Science and Technology. Taipei: NSC.
National Science Foundation. 2006. “National Expenditures for R&D, from Funding Sectors to Performing Sectors.” Available at www.nsf.gov/sbe/srs/nsf03313/tables/tab1b.xls.
Nelson, Philip K. 1970. “Information and Consumer Behavior.” Journal of Political Economy 78(2):311–329.CrossRefGoogle Scholar
Nelson, Philip K. 1974. “Advertising as Information.” Journal of Political Economy 82(4):729–754.CrossRefGoogle Scholar
Neslin, Scott A. 2001. ROI Analysis of Pharmaceutical Promotion (RAPPP). Unpublished study, Hanover, NH, Amos Tuck School of Business, Dartmouth College. Available at www.rxpromoroi.org/rapp.
Neumann, P.J. 2004. “Why Don't Americans Use Cost-Effectiveness Analysis?” American Journal of Managed Care 10: 308–312.Google ScholarPubMed
Newhouse, Joseph P. 2004. “How Much Should Medicare Pay for Drugs?” Health Affairs 23(1):89–102.CrossRefGoogle Scholar
New Zealand Ministry of Health. 2000a. “Direct to Consumer Advertising of Prescription Medicines under Review.” Media release, December 1. Available at www.moh.govt.nz/moh.nsf. Last accessed April 30, 2005.
New Zealand Ministry of Health. 2000b. “Direct-to-Consumer Advertising of Prescription Medicines in New Zealand: A Discussion Paper.” November. Available as dtcaDiscussionDoc.pdf at www.moh.govt.nz/moh.nsf. Last accessed April 30, 2005.
Nexoe, J., Kragstrup, J., and Ronne, T.. 1997. “Impact of Postal Invitations and User Fee on Influenza Vaccination Rates among the Elderly: A Randomized Controlled Trial in General Practice.” Scandinavian Journal of Primary Health Care 15(2):109–112.CrossRefGoogle ScholarPubMed
Nicholson, S., Patricia M. Danzon, and Geoffrey McCullough. 2002. “Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality.” National Bureau of Economic Research Working Paper 9007.
Nordhaus, William D. 2003. “The Health of Nations: The Contribution of Improved Health to Living Standards,” in Measuring the Gains from Medical Research: An Economic Approach,” ed. by Kevin M. Murphy and Robert H. Topel, 9–40. Chicago: University of Chicago Press.Google Scholar
Oeppen, J., and Vaupel, J.W.. 2002. “Demography: Broken Limits to Life Expectancy.” Science 296(5570):1029–1031.CrossRefGoogle ScholarPubMed
Offit, P.A. 2005. “Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?” Health Affairs 24(3):622–30.CrossRefGoogle ScholarPubMed
Ohmit, S.E., Furumotodawson, A., Monto, A.S., and Fasano, N.. 1995. “Influenza Vaccine Use among an Elderly Population in a Community Intervention.” American Journal of Preventive Medicine 11(4):271–276.CrossRefGoogle Scholar
Or, Zeynep. 2003. “Determinants of Health Outcomes in Industrialised Countries: A Pooled, Cross-Country, Time-Series Analysis.” OECD Economic Studies No. 30, 2000/I. Available at www.oecd.org.
Organization for Economic Cooperation and Development. 2004. “Table 1. Life Expectancy in Years,” in OECD Health Data 2004, 3rd ed. Available at www.oecd.org.
Outterson, Kevin. 2004. “The U.S.-Australian Free Trade Agreement's Unfortunate Attack and Good Healthcare Policy.” Comments Submitted to the U.S. Congress, House of Representatives, Committee on Ways and Means, June 22, 2004. Available at www.ita.doc.gov/td/chemicals/phRMA/Outterson%20Response1.pdf. Last accessed October 20, 2005.
Padden, Michael, and Jenkins, Thomas. 2004. “Hatch-Waxman Changes.” National Law Journal, February 23, p. 13.Google Scholar
Palda, Kristian. 1969. Economic Analysis for Marketing Decisions. New York: Prentice-Hall.Google Scholar
Palmer, S., Sculpher, M., Philips, M. Robinson, Ginnelly, L., and Gary, D.. 2005. “Management of Non-ST-Elevation Acute Coronary Syndromes: How Cost-Effective Are Glycoprotein IIb/IIIa Antagonists in the UK National Health Service?” International Journal of Cardiology 100(2):229–240.CrossRefGoogle ScholarPubMed
Pauly, M.V. 1998. Health Benefits at Work: An Economic and Political Analysis of Employment-Based Health Insurance. Ann Arbor: University of Michigan Press.CrossRefGoogle Scholar
Pauly, M.V. 2005. “Improving Vaccine Supply And Development: Who Needs What?” Health Affairs 24(3):680–689.CrossRefGoogle Scholar
Pauly, M.V., Danzon, P., Feldstein, P., and Hoff, J.. 1991. “A Plan for ‘Responsible National Health Insurance.’” Health Affairs 10(1):5–25.CrossRefGoogle Scholar
Pharmaceutical R&D Policy Project. 2005. “The New Landscape of Neglected Disease Drug Development.” London: London School of Economics. Available at www.lse.ac.uk/collections/pressAndInformationOffice/PDF/Neglected_Diseases_05.pdf.
Pharmaceutical Research and Manufacturers of America. 2000. Pharmaceutical Industry Profile. Washington, DC: Pharmaceutical Research and Manufacturing Association.
Pharmaceutical Research and Manufacturers of America. 2005. PhRMA Guiding Principles: Direct to Consumer Advertisements about Prescription Medicines. Washington, DC, August 2005. Available at www.phrma.org.
Philipson, T. 2000. “Economic Epidemiology and Infectious Diseases,” in Handbook of Health Economics, ed. by A.J. Culyer and J.P. Newhouse, 1B: 1761–1769. Amsterdam: Elsevier Science.Google Scholar
Pines, Wayne L. 1999. “A History and Perspective on Direct-to-Consumer Promotion.” Food and Drug Law Journal 54: 489–518.Google ScholarPubMed
Pleis, J., and Gentleman, J.. 2002. “Using the National Health Interview Survey: Time Trends in Influenza Vaccinations among Targeted Adults.” Effective Clinical Practices 5(3 Suppl.):E3.Google ScholarPubMed
Plotkin, S.A. 2005. “Why Certain Vaccines Have Been Delayed or Not Developed at All.” Health Affairs 24(3):631–634.CrossRefGoogle ScholarPubMed
Pogge, T. 2005. “Human Rights and Global Health: A Research Program.” Metaphilosophy 36(1/2):182–209.CrossRefGoogle Scholar
Poikoilainen, K., and Eskola, J.. 1988. “Health Services Resources and Their Relation to Mortality from Causes Amenable to Health Care Intervention: A Cross-national Study.” International Journal of Epidemiology 17(1):86–89.CrossRefGoogle Scholar
Pomerantz, Jay M., Finkelstein, Stan N., Berndt, Ernst R., Poret, Amy W., Walker, Leon E., Alber, Robert C., Kadiyam, Vidya, Das, Mitali, Boss, David T., and Ebert, Thomas H.. 2004. “Prescriber Intent, Off-Label Usage, and Early Discontinuation of Antidepressants.” Journal of Clinical Psychiatry 65(3):395–404.CrossRefGoogle ScholarPubMed
Popp, David. 2001. “Induced Innovation and Energy Prices.” National Bureau of Economic Research Working Paper 8284.
Poulson, David, and Sarah Kellogg. “Private Labs' Ability to Deliver Vaccines Questioned.” Available at www.newhouse.com/archive/story1c110501.html.
Rappuoli, Rino, Miller, Henry I., and Falkow, Stanley. 2002. “The Intangible Value of Vaccination.” Science 297(5583):937–938.CrossRefGoogle ScholarPubMed
Rawlins, M.D., and Culyer, A.J.. 2004. “National Institute for Clinical Excellence and Its Value Judgments.” British Medical Journal 329: 224–227.CrossRefGoogle ScholarPubMed
Reichert, T.A., Sugaya, N., Fedson, D.S., et al. 2001. “The Japanese Experience with Vaccinating Schoolchildren against Influenza.” New England Journal of Medicine 344(12):889–896.CrossRefGoogle ScholarPubMed
Reiffen, David, and Ward, Michael R.. 2005. “Generic Drug Industry Dynamics.” Review of Economics and Statistics 87(1):37–49.CrossRefGoogle Scholar
Reiffen, David, and Ward, Michael. 2006. “Branded Generics as a Strategy to Limit Cannibalization of Pharmaceutical Markets.” Managerial and Decision Economics, forthcoming.Google Scholar
Reinhardt, Uwe E. 1996. “Rationing in Health Care: What It Is, What It Is Not, and Why We Cannot Avoid It,” in Strategic Choices for a Changing Health System, ed. by Stuart H. Altman and E. Uwe, 63–100. Chicago: Health Administration Press.Google Scholar
Reinhardt, Uwe E. 1997. “Making Economic Evaluations More Respectable.” Social Science and Medicine 45(4):555–562.CrossRefGoogle ScholarPubMed
Reinhardt, Uwe E. 2001. “Can Efficiency in Health Care Be Left to the Market?” Journal of Health Politics, Policy and Law 26(5):967–992.CrossRefGoogle Scholar
Reinhardt, Uwe E. 2004. “An Information Infrastructure for the Pharmaceutical Market.” Health Affairs 23(1):107–112.CrossRefGoogle ScholarPubMed
Rice, Thomas H. 2002. The Economics of Health Reconsidered. Chicago: Health Administration Press.Google Scholar
Ridley, R.G. 2004. “Product Development Public-Private Partnerships for Diseases of Poverty,” in Combating Diseases Associated with Poverty, ed. by R. Widdus and K. White. Geneva: Initiative on Public-Private Partnerships for Health.Google Scholar
Riordan, M.H., and Sappington, D.E.M.. 1989. “Second Sourcing.” Rand Journal of Economics 20(1):41–58.CrossRefGoogle Scholar
ROC Department of Health. 2005. Health and Vital Statistical. Taipei: Department of Health.
Rodewald, L., Maes, E., Stevenson, J., et al. 1999. “Immunization Performance Measurement in a Changing Immunization Environment.” Pediatrics 103(4):889–897.Google Scholar
Rogerson, W.P. 1989. “Profit Regulation of Defense Contractors and Prizes for Innovation.” Journal of Political Economy 97(6):1284–1305.CrossRefGoogle Scholar
Rogerson, W.P. 1994. “Economic Incentives and the Defense Procurement Process.” Journal of Economic Perspectives 8(4):65–90.CrossRefGoogle Scholar
Romer, Paul. 1990. “Endogenous Technological Change.” Journal of Political Economy 98: 71–102.CrossRefGoogle Scholar
Rosenthal, Meredith B., Berndt, Ernst R., Donohue, Julie M., Epstein, Arnold M., and Frank, Richard G.. 2003. “Demand Effects of Recent Changes in Prescription Drug Promotion,” chapter 1 in Frontiers in Health Policy Research, vol. 6, ed. Alan M. Garber, 1–26. Cambridge, MA: MIT Press for the National Bureau of Economic Research.Google Scholar
Rosenthal, Meredith B., Berndt, Ernst R., Donohue, Julie M., Frank, Richard G., and Epstein, Arnold M.. 2002. “Promotion of Prescription Drugs to Consumers.” New England Journal of Medicine 346(7):498–505.CrossRefGoogle Scholar
Rosso, R. 2001. “Trends in Food Stamp Program Participation Rates: 1994 to 1999.” Alexandria, VA: United States Department of Agriculture, Food and Nutrition Service.
Rubin, Robert, Hawk, Ann, and Cascade, Elisa. 1998. “PBMs: A Purchaser's Perspective,” in PBMs: Reshaping the Pharmaceutical Distribution Network, ed. by Sheila Shulman, Elaine Healy, and Louis Lasagna, 30. Binghamton, NY: Pharmaceutical Products Press.Google Scholar
Saha, Atanu, Grabowski, Henry, Birnbaum, Howard, Greenberg, Paul, and Bizan, Oded. 2006. “Generic Competition in the U.S. Pharmaceutical Industry.” International Journal of the Economics of Business 13(1):15–38.CrossRefGoogle Scholar
Salkever, D., and Frank, R.. 1996. “Economic Issues in Vaccine Purchase Agreements,” in Supplying Vaccine: An Economic Analysis of Critical Issues, ed. by M. Pauly, C.A. Robinson, S. Sepe, M. Sing, and M.K. Willian. Amsterdam: IOS Press.Google Scholar
Satterthwaite, P. 1997. “A Randomised Intervention Study to Examine the Effect on Immunisation Coverage of Making Influenza Vaccine Available at No Cost.” New Zealand Medical Journal 110(1038):58–60.Google ScholarPubMed
Saunders, Barrie. 2003. “Direct to Consumer Advertising of Prescription Drugs in New Zealand: Professors' Protest to Government Placed under the Microscope.” Wellington, New Zealand: Saunders Unsworth. Available at www.sul.co.nz.
Scharfstein, D. 1988. “The Disciplinary Role of Takeovers.” Review of Economic Studies 55(2):185–199.CrossRefGoogle Scholar
Scherer, F.M. 2000. “The Pharmaceutical Industry,” in Handbook of Health Economics, vol. 1, ed. by A.J. Culyer and J.P. Newhouse, 297–336. Amsterdam: Elsevier Science.Google Scholar
Scherer, F.M. 2001. “The Link between Gross Profitability and Pharmaceutical R&D Spending.” Health Affairs 20: 216–220.CrossRefGoogle ScholarPubMed
Scherer, F.M., and Ross, D.R.. 1990. Industrial Market Structure and Economic Performance. 3rd ed. Boston: Houghton-Mifflin.Google Scholar
Schmalensee, R. 1979. The Control of National Monopolies. Lexington, MA: D.C. Heath, Lexington Books.Google Scholar
Schmookler, Jacob. 1966. Invention and Economic Growth. Cambridge, MA: Harvard University Press.CrossRefGoogle Scholar
Schwartzman, David, and Cognato, Antonio. 1996. “Has Pharmaceutical Research Become More Scientific?” Review of Industrial Organization 11: 841–851.CrossRefGoogle Scholar
Schweitzer, Stuart. 1997. Pharmaceuticals, Economics, and Policy. New York: Oxford University Press.Google Scholar
Scotchmer, S. 2004. Innovation and Incentives. Cambridge, MA: MIT Press.Google Scholar
Scott Morton, F.M. 1999. “Entry Decisions in the Generic Pharmaceutical Industry.” RAND Journal of Economics 30(3):421–440.CrossRefGoogle Scholar
Scott Morton, F.M. 2000. “Barriers to Entry Brand Advertising, and Generic Entry in the U.S. Pharmaceutical Industry.” International Journal of Industrial Organization 18(7):1085–1104.CrossRefGoogle Scholar
Scriabiane, Alexander. 1999. “The Role of Biotechnology in Drug Development,” in Pharmaceutical Innovation: Revolutionizing Human Health, ed. by Ralph Landau, Basil Achilladelis, and Alexander Scriabine. Philadelphia: Chemical Heritage Foundation Press.Google Scholar
Sculpher, M.J., Pang, F.S., Manca, A., Drummond, M.F., Golder, S., Urdahl, H., Davies, L.M., and Eastwood, A.. 2004. Generalisability in Economic Evaluation Studies in Health Care: A Review and Case Studies. Health Technology Assessment 8(49) (whole issue).CrossRefGoogle Scholar
Shavell, S., and Ypersele, T.. 2001. “Rewards versus Intellectual Property Rights.” Journal of Law and Economics 44(2):525–547.CrossRefGoogle Scholar
Shaw, James W., Horrace, William C., and Vogel, Ronald J.. 2005. “The Determinants of Life Expectancy: An Analysis of the OECD Health Data.” Southern Economic Journal 71(4):768–783.CrossRefGoogle Scholar
Shleifer, Andrei. 1998. “State versus Private Ownership.” Journal of Economic Perspectives 12(4):133–150.CrossRefGoogle Scholar
Shleifer, A., and Vishny, R.. 1994. “Politicians and Firms.” Quarterly Journal of Economics 109: 995–1025.CrossRefGoogle Scholar
Siegel, Jonathan B. 2004. “Financial Aspects of 180-Day Generic Exclusivity.” Presentation to the Food and Drug Law Institute Conference on Two Decades of Hatch-Waxman, December 1–2, Washington, DC.
Sinclair, G., Klepper, S., and Cohen, W.. 2000. “What's Experience Got to Do with It? Sources of Cost Reduction in a Large Specialty Chemicals Producer.” Management Science 46(1):25–28.CrossRefGoogle Scholar
Skinner, J., and Wennberg, J.E.. 2000. “How Much Is Enough? Efficiency and Medicare Spending in the Last Six Months of Life,” in The Changing Hospital Industry: Comparing Not-for-Profit and For-Profit Institutions, ed. by David Cutler, 169–193. Chicago: University of Chicago Press.Google Scholar
Sloan, Frank A., and Conover, Chris J.. 1998. “Effects of State Reforms on Health Insurance Coverage of Adults.” Inquiry 35: 280–293.Google ScholarPubMed
Sloan, Frank A., and Grabowski, Henry G.. 1997. “Introduction and Overview.” Social Science and Medicine 54(4):505–510.CrossRefGoogle Scholar
Sloan, Frank A., Whetten-Goldstein, K., and Wilson, A.. 1997. “Hospital Pharmacy Decisions, Cost Containment, and the Use of Cost-Effectiveness Analysis.” Social Science and Medicine 54(4):525–536.Google Scholar
Smith, J.S. 1990. Patenting the Sun. New York: Morrow.Google Scholar
Song, F., Altman, D.G., Glenny, A.M., and Deeks, J.. 2003. “Validity of Indirect Comparison for Estimating Efficacy of Competing Interventions: Empirical Evidence from Published Meta-Analyses.” British Medical Journal 326: 472–478.CrossRefGoogle ScholarPubMed
Sorenson, Alan T. 2000. “Equilibrium Price Dispersion in Retail Markets for Prescription Drugs.” Journal of Political Economy 108(4):833–850.CrossRefGoogle Scholar
Spence, M. 1984. “Cost Reduction, Competition, and Industry Performance.” Econometrica 52: 101–121.CrossRefGoogle Scholar
Spulber, D. 1989. Regulation and Markets.Cambridge, MA: MIT Press.Google Scholar
Stapleton, S. 2004. “Project BioShield.” American Medical News 47(31):19.Google Scholar
Canada, Statistics. 1974. Life Tables, Canada and Provinces, 1970–1972. Ottawa: Minister of Industry.Google Scholar
Canada, Statistics. 2002. Life Tables, Canada, Provinces and Territories, 1995–1997. Ottawa: Minister of Industry.Google Scholar
Stein, J.C. 1988. “Takeover Threats and Managerial Myopia.” Journal of Political Economy 96(1):61–80.CrossRefGoogle Scholar
Stern, Scott, Michael E. Porter, and Jeffrey L. Furman. 2000. “The Determinants of National Innovative Capacity.” National Bureau of Economics Research Working Paper 7876.
Stinnett, A.A., et al. 1996. “The Cost Effectiveness of Dietary and Pharmacologic Therapy for Cholesterol Reduction in Adults,” in Cost Effectiveness in Health and Medicine, ed. by M. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein, 349–391. Oxford: Oxford University Press.Google Scholar
Stratton, K.R., Durch, J.S., and Lawrence, R.S.. 2000. Vaccines for the 21st Century: A Tool for Decision-Making. Washington, DC: Institute of Medicine, National Academy Press.Google Scholar
Summers, L.H. 1989. “What Can Economics Contribute to Social Policy?” American Economic Review 79(2):177–183.Google Scholar
Tan, Litjen, and the American Medical Association, . 2006. “Strengthening the Supply of Routinely Recommended Vaccines in the United States: A Perspective from the American Medical Association.” Clinical Infectious Diseases 42(Suppl. 3): S121–S124.CrossRefGoogle ScholarPubMed
Taylor, C.R. 1995. “Digging for Golden Carrots: An Analysis of Research Tournaments.” American Economic Review 85(4):872–890.Google Scholar
Temin, Peter. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press.CrossRefGoogle Scholar
Thomas, P. 2002. “The Economics of Vaccines.” Harvard Medical International (HMI) World, September/October.Google Scholar
Tobin, James. 1969. “A General Equilibrium Approach to Monetary Theory.” Journal of Money, Credit, and Banking 1(1):15–29.CrossRefGoogle Scholar
Toop, Les, Dee Richards, Tony Dowell, Murray Tilyard, Tony Fraser, and Bruce Arrol. 2003. “Direct to Consumer Advertising of Prescription Drugs in New Zealand: For Health or for Profit?” Report to the Minister of Health Supporting the Case for a Ban on DTCA, February. Available at www.chmeds.ac.nz/report.pdf. Last accessed April 30, 2005.
Towse, A. 2004. “Developing the Idea of Transferable Intellectual Property Rights (TIPP) to Incentivize R&D in Drugs and Vaccines for Neglected Diseases.” Office of Health Economics, London, March 2, Appendix I, 22–24.
Towse, A., and H. Kettler. 2005. “Review of IP and Non-IP Incentives for R&D for Diseases of Poverty: What Type of Innovation Is Required and How Can We Incentivise the Private Sector to Deliver It?” Available at www.who.int/intellectualproperty/studies/health_innovation/en. Last accessed May 10, 2005.
Towse, A., Mestre-Fernandez, J., and Renowden, O.. 2004. “Estimates of the Medium Term Financial Resource Needs for Development of Pharmaceuticals to Combat ‘Neglected Diseases,’” in Combating Diseases Associated with Poverty, ed. by R. Widdus and K. White. Geneva: Initiative on Public-Private Partnerships for Health.Google Scholar
Tufts Center for the Study of Drug Development. 2003. “Total Cost to Develop a New Prescription Drug, Including Cost of Post-Approval Research, Is $897 million.” Press release, May 13, 2003. Available at www.csdd.tufts.edu.
Turner, Margaret A. 2003. “Strengths and Weaknesses of the Housing Voucher Program.” Congressional Testimony prepared for the Committee on Financial Services, Subcommittee on Housing and Community Opportunity, U.S. House of Representatives, June 17, 2003. Available at www.urban.org/url.cfm?ID=900635.
U.S. Centers for Disease Control and Prevention. 1999. “An Ounce of Prevention … What Are the Returns?” 2nd ed. Available at www.cdc.gov/epo/prevent.htm.
U.S. Centers for Disease Control and Prevention. 2002a. “Influenza and Pneumococcal Vaccination Levels among Persons Aged > 65 years, United States, 2001.” Morbidity and Mortality Weekly Report 51(45):1019–1024.
U.S. Centers for Disease Control and Prevention. 2002b. “National, State, and Urban Area Vaccination Coverage Levels among Children Aged 19–35 Months: United States, 2001.” Morbidity and Mortality Weekly Report 3: 664–666.
U.S. Centers for Disease Control and Prevention. 2003. “National, State, and Urban Area Vaccination Coverage Levels among Children Aged 19–35 Months: United States, 2002.” Morbidity and Mortality Weekly Report 52(31):728–732.
U.S. Centers for Disease Control and Prevention. 2004. “Influenza Viruses.” Available at www.cdc.gov/flu/avian/gen-info/flu-viruses.htm. Last accessed March 2, 2005.
U.S. Centers for Disease Control and Prevention. 2005a. “Influenza Pandemics.” Available at www.cdc.gov/flu/avian/gen-info/pandemics.htm. Last accessed March 2, 2005.
U.S. Centers for Disease Control and Prevention. 2005b. “Avian Influenza Infection in Humans.” Available at www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm. Last accessed March 2, 2005.
U.S. Centers for Medicaid and Medicare Services. 2003. “The Nation's Health Care Dollar: 2001.” Washington, DC: Government Printing Office.
U.S. Committee on Ways and Means, U.S. House of Representatives. 2003. Background Material and Data on the Programs within the Jurisdiction of the Committee on Ways and Means. (Informally known as the “Green Book.”) WMCP 108–6. Washington, DC: Government Printing Office.
U.S. Congressional Budget Office. 1998. “How Increased Competition Has Affected Prices and Returns in the Pharmaceutical Industry.” July, 38. Washington, DC: Government Printing Office.
U.S. Department of Health and Human Services. 2002. “Payment by Results” Breakthrough Ends Years of Uncertainty for MS Patients: Agreement Follows Recommendation from NICE. Washington, DC: Government Printing Office.
U.S. Department of Health and Human Services. 2004. “Pandemic Influenza Preparedness and Response Plan,” 1–54. Washington, DC: Government Printing Office.
U.S. Food and Drug Administration. 1999. “Creating a Risk Management Framework: Report to the FDA Commissioner from the Task Force on Risk Management.” Washington, DC: Government Printing Office.
U.S. Food and Drug Administration. 2005. “CDER NDAs Approved in Calendar Years 1990–2204 by Therapeutic Potential and Chemical Type.” Available at www.fda.gov/cder/rdmt/pstable.htm.
U.S. Senate. 1960–. Administered Prices in the Drug Industry. Hearings before the Sub-Committee on Antitrust and Monopoly, 86th Congress, 1959 and 1960, Part 18. Washington, DC: Government Printing Office.
U.S. Senate, Republican Policy Committee. 2005. “Pharmaceutical Price Controls Abroad: An Unfair Trade Policy.” Available at www.kyl.senate.gov/legis_center/rpc_110603.pdf. Last accessed October 20, 2005.
Vernon, John M. 1981. “Concentration, Promotion, and Market Share Stability in the Pharmaceutical Industry.” Journal of Industrial Economics 19(3):246–266.CrossRefGoogle Scholar
Vernon, J., and Grabowski, H.. 2000. “The Distribution of Sales Revenues from Pharmaceutical Innovation.” PharmoEconomics 18(1):21–32.Google Scholar
Vernon, John M., and Gusen, Peter. 1974. “Technical Change and Firm Size: Pharmaceutical Industry.” Review of Economics and Statistics 56: 294–302.CrossRefGoogle Scholar
Viscusi, W. Kip. 1993. “The Value of Risks to Life and Health.” Journal of Economic Literature 31: 1912–1946.Google Scholar
Viscusi, W. Kip. 1995. “Discounting Health Effects for Medical Decisions,” in Valuing Health Care, ed. Frank Sloan, 125–147. Cambridge: Cambridge University Press.Google Scholar
Viscusi, W. Kip, and Aldy, Joseph E.. 2003. “The Value of a Statistical Life: A Critical Review of Market Estimates throughout the World.” Journal of Risk and Uncertainty 27(1):5–76.CrossRefGoogle Scholar
Vistnes, G. 1994. “An Empirical Investigation of Procurement Contract Structures.” Rand Journal of Economics 25(2):215–241.CrossRefGoogle ScholarPubMed
Walsh, J.P., Arora, A., and Cohen, W.M.. 2003. “Working through the Patent Problem.” Science 299(5609):1021.CrossRefGoogle ScholarPubMed
Weissman, Joel S., Blumenthal, David, Silk, Alvin J., Newman, Michael, Zapert, Kinga, Leitman, Robert, and Feibelmann, Sandra. 2004. “Physicians Report on Patient Encounters Involving Direct-to-Consumer Advertising.” Health Affairs – Web Exclusive W4: 219–233.Google Scholar
WHO. 2004. World Health Report, Revised Global Burden of Disease 2002 Estimates. London: WHO.
WHO Collaborating Centre for Drug Statistics Methodology. 2004. “Guidelines for ATC Classification and DDD Assignment.” Oslo: Norwegian Institute.
Widdus, Roy, and Katherine White. 2004. “Combating Diseases of Poverty: Financing Strategies for Product Development and the Potential Role of Private-Public Partnerships.” Geneva: Initiative on Private-Public Partnerships for Health.
Wilby, J., Kainth, A., Hawkins, N., Epstein, D., McDaid, C., et al. 2003. A Rapid and Systematic Review of the Clinical Effectiveness, Tolerability and Cost-Effectiveness of Newer Drugs for Epilepsy in Adults. Report to the National Institute for Clinical Excellence, forthcoming.Google Scholar
Willan, A.R., Pinto, E.M., O'Brien, B.J., et al. 2005. “Country Specific Cost Comparisons from Multinational Clinical Trials Using Empirical Bayesian Shrinkage Estimation: The Canadian ASSENT-3 Economic Analysis.” Health Economics 14(1):327–338.CrossRefGoogle ScholarPubMed
Wittink, Richard R. 2002. “Analysis of ROI for Pharmaceutical Promotions,” September, video presentation, Association of Medical Publications. Available at www.vioworks.com/clients/amp.
Wosinska, Marta. 2002. “Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products.” Harvard Business School, Marketing Research Paper Series, No. 02-04.
Wosinska, Marta. 2005. “Direct-to-Consumer Advertising and Drug Therapy Compliance.” Journal of Marketing Research 42(3):323–332.CrossRefGoogle Scholar
Wright, Brian D. 1983. “The Economics of Invention Incentives: Patents, Prizes, and Research Contracts.” American Economic Review 73: 691–707.Google Scholar
Zucker, Lynne E., Darby, Michael R., and Brewer, Marilynn B.. 1998. “Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises.” American Economic Review 88(1):290–306.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • References
  • Edited by Frank A. Sloan, Duke University, North Carolina, Chee-Ruey Hsieh, Academia Sinica, Taipei, Taiwan
  • Book: Pharmaceutical Innovation
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511618871.017
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • References
  • Edited by Frank A. Sloan, Duke University, North Carolina, Chee-Ruey Hsieh, Academia Sinica, Taipei, Taiwan
  • Book: Pharmaceutical Innovation
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511618871.017
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • References
  • Edited by Frank A. Sloan, Duke University, North Carolina, Chee-Ruey Hsieh, Academia Sinica, Taipei, Taiwan
  • Book: Pharmaceutical Innovation
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511618871.017
Available formats
×